US20220287862A1 - Topical treatment for anorectal disorders with and without seat cushion - Google Patents
Topical treatment for anorectal disorders with and without seat cushion Download PDFInfo
- Publication number
- US20220287862A1 US20220287862A1 US17/804,342 US202217804342A US2022287862A1 US 20220287862 A1 US20220287862 A1 US 20220287862A1 US 202217804342 A US202217804342 A US 202217804342A US 2022287862 A1 US2022287862 A1 US 2022287862A1
- Authority
- US
- United States
- Prior art keywords
- anorectal
- supplements
- hemorrhoids
- fda
- ingredients
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000011282 treatment Methods 0.000 title abstract description 53
- 230000000699 topical effect Effects 0.000 title abstract description 36
- 208000015815 Rectal disease Diseases 0.000 title abstract description 23
- 239000004480 active ingredient Substances 0.000 claims description 47
- 239000013589 supplement Substances 0.000 claims description 44
- 239000000203 mixture Substances 0.000 claims description 37
- 230000036407 pain Effects 0.000 claims description 27
- 230000000694 effects Effects 0.000 claims description 25
- 230000004054 inflammatory process Effects 0.000 claims description 24
- 206010061218 Inflammation Diseases 0.000 claims description 20
- 239000006185 dispersion Substances 0.000 claims description 9
- 230000007794 irritation Effects 0.000 claims description 9
- 230000029663 wound healing Effects 0.000 claims description 9
- 230000000740 bleeding effect Effects 0.000 claims description 8
- 208000005392 Spasm Diseases 0.000 claims description 7
- 230000001914 calming effect Effects 0.000 claims description 7
- 230000002792 vascular Effects 0.000 claims description 7
- 208000007101 Muscle Cramp Diseases 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 239000004599 antimicrobial Substances 0.000 claims description 5
- 238000001647 drug administration Methods 0.000 claims description 2
- 230000001747 exhibiting effect Effects 0.000 claims description 2
- 230000000638 stimulation Effects 0.000 abstract description 7
- 208000014617 hemorrhoid Diseases 0.000 description 68
- 239000004615 ingredient Substances 0.000 description 44
- 208000024891 symptom Diseases 0.000 description 30
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 19
- 239000000499 gel Substances 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- 229960001802 phenylephrine Drugs 0.000 description 15
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 15
- 230000008961 swelling Effects 0.000 description 15
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 14
- 208000003251 Pruritus Diseases 0.000 description 13
- 229960004194 lidocaine Drugs 0.000 description 13
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 12
- 230000007803 itching Effects 0.000 description 12
- 239000011787 zinc oxide Substances 0.000 description 11
- 235000014692 zinc oxide Nutrition 0.000 description 11
- 239000002674 ointment Substances 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 10
- 230000000153 supplemental effect Effects 0.000 description 10
- 239000005526 vasoconstrictor agent Substances 0.000 description 10
- 230000003444 anaesthetic effect Effects 0.000 description 9
- 230000003110 anti-inflammatory effect Effects 0.000 description 9
- 239000000284 extract Substances 0.000 description 9
- 235000011187 glycerol Nutrition 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 8
- 235000014787 Vitis vinifera Nutrition 0.000 description 8
- 230000000202 analgesic effect Effects 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 239000003589 local anesthetic agent Substances 0.000 description 8
- 208000032843 Hemorrhage Diseases 0.000 description 7
- 229940124091 Keratolytic Drugs 0.000 description 7
- 108010016731 PPAR gamma Proteins 0.000 description 7
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 7
- 240000006365 Vitis vinifera Species 0.000 description 7
- 230000001139 anti-pruritic effect Effects 0.000 description 7
- 239000003908 antipruritic agent Substances 0.000 description 7
- 210000000436 anus Anatomy 0.000 description 7
- 238000001816 cooling Methods 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 230000001530 keratinolytic effect Effects 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 206010002153 Anal fissure Diseases 0.000 description 6
- 208000016583 Anus disease Diseases 0.000 description 6
- 208000009531 Fissure in Ano Diseases 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 210000000689 upper leg Anatomy 0.000 description 6
- 208000019751 Anorectal disease Diseases 0.000 description 5
- 206010036772 Proctalgia Diseases 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 229920002125 Sokalan® Polymers 0.000 description 5
- 229940105847 calamine Drugs 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000003995 emulsifying agent Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 229910052864 hemimorphite Inorganic materials 0.000 description 5
- 239000006210 lotion Substances 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- CPYIZQLXMGRKSW-UHFFFAOYSA-N zinc;iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+3].[Fe+3].[Zn+2] CPYIZQLXMGRKSW-UHFFFAOYSA-N 0.000 description 5
- 240000007436 Cananga odorata Species 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 206010036774 Proctitis Diseases 0.000 description 4
- 229930003427 Vitamin E Natural products 0.000 description 4
- 235000009754 Vitis X bourquina Nutrition 0.000 description 4
- 235000012333 Vitis X labruscana Nutrition 0.000 description 4
- 239000001140 aloe barbadensis leaf extract Substances 0.000 description 4
- 210000002255 anal canal Anatomy 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 229940044949 eucalyptus oil Drugs 0.000 description 4
- 239000010642 eucalyptus oil Substances 0.000 description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 4
- 235000002532 grape seed extract Nutrition 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- -1 light mineral oil Substances 0.000 description 4
- 210000000664 rectum Anatomy 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 235000019165 vitamin E Nutrition 0.000 description 4
- 229940046009 vitamin E Drugs 0.000 description 4
- 239000011709 vitamin E Substances 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 240000003538 Chamaemelum nobile Species 0.000 description 3
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 3
- 244000163122 Curcuma domestica Species 0.000 description 3
- 235000003392 Curcuma domestica Nutrition 0.000 description 3
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 244000269722 Thea sinensis Species 0.000 description 3
- 235000006468 Thea sinensis Nutrition 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229920002770 condensed tannin Polymers 0.000 description 3
- 235000003373 curcuma longa Nutrition 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000001953 sensory effect Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 235000013976 turmeric Nutrition 0.000 description 3
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 241000208140 Acer Species 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 241000157282 Aesculus Species 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- OVSQVDMCBVZWGM-IDRAQACASA-N Hirsutrin Natural products O([C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1)C1=C(c2cc(O)c(O)cc2)Oc2c(c(O)cc(O)c2)C1=O OVSQVDMCBVZWGM-IDRAQACASA-N 0.000 description 2
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 244000294611 Punica granatum Species 0.000 description 2
- 235000014360 Punica granatum Nutrition 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000005299 abrasion Methods 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical group OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 2
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 2
- 230000003872 anastomosis Effects 0.000 description 2
- 235000010208 anthocyanin Nutrition 0.000 description 2
- 239000004410 anthocyanin Substances 0.000 description 2
- 229930002877 anthocyanin Natural products 0.000 description 2
- 150000004636 anthocyanins Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000001217 buttock Anatomy 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N cholecalciferol group Chemical group C[C@@]12CCC/C(/[C@@H]2CC[C@@H]1[C@H](C)CCCC(C)C)=C\C=C/1\C[C@H](CCC1=C)O QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 235000012716 cod liver oil Nutrition 0.000 description 2
- 239000003026 cod liver oil Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000035597 cooling sensation Effects 0.000 description 2
- 235000012754 curcumin Nutrition 0.000 description 2
- 239000004148 curcumin Substances 0.000 description 2
- 229940109262 curcumin Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 235000010181 horse chestnut Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000030214 innervation Effects 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 201000007772 internal hemorrhoid Diseases 0.000 description 2
- GXMWXESSGGEWEM-UHFFFAOYSA-N isoquercitrin Natural products OCC(O)C1OC(OC2C(Oc3cc(O)cc(O)c3C2=O)c4ccc(O)c(O)c4)C(O)C1O GXMWXESSGGEWEM-UHFFFAOYSA-N 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 239000000171 lavandula angustifolia l. flower oil Substances 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 201000007783 perianal hematoma Diseases 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- OVSQVDMCBVZWGM-QSOFNFLRSA-N quercetin 3-O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-QSOFNFLRSA-N 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 239000010686 shark liver oil Substances 0.000 description 2
- 229940069764 shark liver oil Drugs 0.000 description 2
- 210000005125 simple columnar epithelium Anatomy 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000001732 thrombotic effect Effects 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 235000005282 vitamin D3 Nutrition 0.000 description 2
- 239000011647 vitamin D3 Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 229940021056 vitamin d3 Drugs 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 1
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 1
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 229940013085 2-diethylaminoethanol Drugs 0.000 description 1
- AUVALWUPUHHNQV-UHFFFAOYSA-N 2-hydroxy-3-propylbenzoic acid Chemical class CCCC1=CC=CC(C(O)=O)=C1O AUVALWUPUHHNQV-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010068286 Anorectal discomfort Diseases 0.000 description 1
- 241000945470 Arcturus Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 235000009024 Ceanothus sanguineus Nutrition 0.000 description 1
- 244000146462 Centella asiatica Species 0.000 description 1
- 235000004032 Centella asiatica Nutrition 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 235000016795 Cola Nutrition 0.000 description 1
- 244000228088 Cola acuminata Species 0.000 description 1
- 241000106022 Colomerus vitis Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 244000105038 Eucalyptus stuartiana Species 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 241000208690 Hamamelis Species 0.000 description 1
- 206010061217 Infestation Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 240000003553 Leptospermum scoparium Species 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 235000019493 Macadamia oil Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- DUBCCGAQYVUYEU-VFKUPZNOSA-N Miquelianin Natural products O=C(O)[C@@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](OC2=C(c3cc(O)c(O)cc3)Oc3c(c(O)cc(O)c3)C2=O)O1 DUBCCGAQYVUYEU-VFKUPZNOSA-N 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 235000009421 Myristica fragrans Nutrition 0.000 description 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- 206010033372 Pain and discomfort Diseases 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 1
- 102100038831 Peroxisome proliferator-activated receptor alpha Human genes 0.000 description 1
- 102100038824 Peroxisome proliferator-activated receptor delta Human genes 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- SYCBXBCPLUFJID-UHFFFAOYSA-N Pramoxine hydrochloride Chemical compound Cl.C1=CC(OCCCC)=CC=C1OCCCN1CCOCC1 SYCBXBCPLUFJID-UHFFFAOYSA-N 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- DUBCCGAQYVUYEU-UHFFFAOYSA-N Querciturone Natural products O1C(C(O)=O)C(O)C(O)C(O)C1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O DUBCCGAQYVUYEU-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010038063 Rectal haemorrhage Diseases 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 102000034527 Retinoid X Receptors Human genes 0.000 description 1
- 108010038912 Retinoid X Receptors Proteins 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- PPWHTZKZQNXVAE-UHFFFAOYSA-N Tetracaine hydrochloride Chemical compound Cl.CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 PPWHTZKZQNXVAE-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000695 adrenergic alpha-agonist Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229960004220 alcloxa Drugs 0.000 description 1
- 102000004305 alpha Adrenergic Receptors Human genes 0.000 description 1
- 108090000861 alpha Adrenergic Receptors Proteins 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000010478 argan oil Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 239000004204 candelilla wax Substances 0.000 description 1
- 235000013868 candelilla wax Nutrition 0.000 description 1
- 229940073532 candelilla wax Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 229960001747 cinchocaine Drugs 0.000 description 1
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 description 1
- IVHBBMHQKZBJEU-UHFFFAOYSA-N cinchocaine hydrochloride Chemical compound [Cl-].C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCC[NH+](CC)CC)=C21 IVHBBMHQKZBJEU-UHFFFAOYSA-N 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 238000001246 colloidal dispersion Methods 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229960001985 dextromethorphan Drugs 0.000 description 1
- VTKMMWSAJLCWSM-UHFFFAOYSA-H dialuminum;5-(carbamoylamino)-2-oxo-1,5-dihydroimidazol-4-olate;chloride;tetrahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[Al+3].[Al+3].[Cl-].NC(=O)NC1NC(=O)N=C1[O-] VTKMMWSAJLCWSM-UHFFFAOYSA-H 0.000 description 1
- 229940045574 dibucaine hydrochloride Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- MZNZKBJIWPGRID-UHFFFAOYSA-N diphenylphosphorylmethyl(diphenyl)phosphane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=O)CP(C=1C=CC=CC=1)C1=CC=CC=C1 MZNZKBJIWPGRID-UHFFFAOYSA-N 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- KNZADIMHVBBPOA-UHFFFAOYSA-N dyclonine hydrochloride Chemical compound [Cl-].C1=CC(OCCCC)=CC=C1C(=O)CC[NH+]1CCCCC1 KNZADIMHVBBPOA-UHFFFAOYSA-N 0.000 description 1
- 229960003462 dyclonine hydrochloride Drugs 0.000 description 1
- 210000003981 ectoderm Anatomy 0.000 description 1
- 238000005485 electric heating Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 210000001900 endoderm Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229960004842 ephedrine sulfate Drugs 0.000 description 1
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 1
- 235000012734 epicatechin Nutrition 0.000 description 1
- 238000002692 epidural anesthesia Methods 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 229960003072 epinephrine hydrochloride Drugs 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 210000005071 external anal sphincter Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N flavone Chemical compound O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 229940107131 ginseng root Drugs 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 229930182480 glucuronide Natural products 0.000 description 1
- 150000008134 glucuronides Chemical class 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940116364 hard fat Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000001632 homeopathic effect Effects 0.000 description 1
- 229940014041 hyaluronate Drugs 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 210000005072 internal anal sphincter Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 239000008633 juniper tar Substances 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229940059904 light mineral oil Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000010469 macadamia oil Substances 0.000 description 1
- 239000001115 mace Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- DUBCCGAQYVUYEU-ZUGPOPFOSA-N miquelianin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O DUBCCGAQYVUYEU-ZUGPOPFOSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- RGUVUPQQFXCJFC-UHFFFAOYSA-N n-hydroxyoctanamide Chemical compound CCCCCCCC(=O)NO RGUVUPQQFXCJFC-UHFFFAOYSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 102000006255 nuclear receptors Human genes 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 210000002824 peroxisome Anatomy 0.000 description 1
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 1
- 108091008765 peroxisome proliferator-activated receptors β/δ Proteins 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- OCYSGIYOVXAGKQ-FVGYRXGTSA-N phenylephrine hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=CC(O)=C1 OCYSGIYOVXAGKQ-FVGYRXGTSA-N 0.000 description 1
- 229960003733 phenylephrine hydrochloride Drugs 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000001738 pogostemon cablin oil Substances 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 210000004258 portal system Anatomy 0.000 description 1
- RWPGFSMJFRPDDP-UHFFFAOYSA-L potassium metabisulfite Chemical compound [K+].[K+].[O-]S(=O)S([O-])(=O)=O RWPGFSMJFRPDDP-UHFFFAOYSA-L 0.000 description 1
- 229940043349 potassium metabisulfite Drugs 0.000 description 1
- 235000010263 potassium metabisulphite Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229940019974 pramoxine hydrochloride Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000011253 protective coating Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- LOJXBHNAFUDMIQ-UHFFFAOYSA-N quercetin-3-alpha-glucuronide Natural products OC1OC(C(O)C(O)C1O)C(=O)Oc1c(oc2cc(O)cc(O)c2c1=O)-c1ccc(O)c(O)c1 LOJXBHNAFUDMIQ-UHFFFAOYSA-N 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000010667 rosehip oil Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 238000009958 sewing Methods 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 238000002693 spinal anesthesia Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 210000005127 stratified epithelium Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229960002372 tetracaine Drugs 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- 229960002494 tetracaine hydrochloride Drugs 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 238000000015 thermotherapy Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 229940100611 topical cream Drugs 0.000 description 1
- 229940100615 topical ointment Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000004855 vascular circulation Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000001631 vena cava inferior Anatomy 0.000 description 1
- 201000002282 venous insufficiency Diseases 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 229940072358 xylocaine Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F5/00—Orthopaedic methods or devices for non-surgical treatment of bones or joints; Nursing devices; Anti-rape devices
- A61F5/0093—Rectal devices, e.g. for the treatment of haemorrhoids
-
- A—HUMAN NECESSITIES
- A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
- A47C—CHAIRS; SOFAS; BEDS
- A47C7/00—Parts, details, or accessories of chairs or stools
- A47C7/02—Seat parts
- A47C7/18—Seat parts having foamed material included in cushioning part
-
- A—HUMAN NECESSITIES
- A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
- A47C—CHAIRS; SOFAS; BEDS
- A47C7/00—Parts, details, or accessories of chairs or stools
- A47C7/62—Accessories for chairs
- A47C7/72—Adaptations for incorporating lamps, radio sets, bars, telephones, ventilation, heating or cooling arrangements or the like
- A47C7/74—Adaptations for incorporating lamps, radio sets, bars, telephones, ventilation, heating or cooling arrangements or the like for ventilation, heating or cooling
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/122—Foams; Dry foams
Definitions
- the present invention relates to medical treatments for anorectal disorders and, more particularly, to a topical treatment for anorectal disorders with and without seat cushion; specifically, internal and externally applied topical products (ointments, creams, lotions, suppositories, gels, wipes, etc.) which aid in relieving or protecting from various symptoms of anorectal disease or disorders such as burning, itching, irritation, pain or mild inflammation of the skin or mucous membranes associated with various anorectal disorders which may include but not to be inclusive of internal and external hemorrhoids, anal fissures, proctitis, cryptitis and the method of using such topical treatments, as well as using a contoured seat cushion with a temperature adaptive insert gel or electrothermal heat pad insert.
- Hemorrhoids are one of the most common causes of anorectal pathology. Subsequently, hemorrhoids are blamed for virtually any anorectal complaint by patients and medical professionals alike even though there are other distinct or contributing disorders such as anal fissures, proctitis, cryptitis, etc. Confusion often arises because the term “hemorrhoid” has been used to refer to both normal anatomical structures and pathological structures. In the context of this application, “hemorrhoids” refers to the pathological presentation of hemorrhoidal venous cushions.
- Hemorrhoidal venous cushions are normal structures of the anorectum and are universally present unless a prior surgical intervention has taken place. Because of their rich vascular supply, highly sensitive location, and tendency to engorge and prolapse, they are common causes of anal pathology. Symptoms can range from mildly bothersome, such as itching with is referred to as pruritus, to quite concerning, such as rectal bleeding. While it is a common condition diagnosed in clinical practice, many patients are too embarrassed to ever seek treatment. Consequently, the true prevalence of pathologic hemorrhoids is not known.
- Hemorrhoidal venous cushions are a normal part of the human anorectum and arise from subepithelial connective tissue within the anal canal. Present in utero, these cushions surround and support distal anastomoses between the superior rectal arteries and the superior, middle, and inferior rectal veins. They also contain a subepithelial smooth muscle layer, contributing to the bulk of the cushions. Normal hemorrhoidal tissue accounts for approximately 15-20% of resting anal pressure and provides important sensory information, enabling the differentiation between solid, liquid, and gas.
- Hemorrhoids are classified by their anatomic origin within the anal canal and by their position relative to the dentate line.
- the dentate line is between the simple columnar epithelium of the rectum and the stratified epithelium of the anal canal.
- Internal hemorrhoids develop above the dentate line from embryonic endoderm. They are covered by the simple columnar epithelium of anal mucosa and lack typical somatic sensory innervation. Therefore, people who have swollen or inflamed internal hemorrhoids in isolation without coexisting pathology do not contribute to the majority of people who suffer from anorectal pain as their primary symptom.
- External hemorrhoids develop from ectoderm and arise distal to the dentate line. They are covered by stratified squamous epithelium and receive somatic sensory innervation from the inferior rectal nerve rendering them painful when irritated, painful, swollen or thrombosed.
- the most common symptom of internal hemorrhoids is bright red blood covering the stool, on toilet paper, or in the toilet bowl.
- an internal hemorrhoid may protrude through the anus outside the body, becoming irritated and painful. This is known as a protruding or prolapsing internal hemorrhoid. Sudden external swelling is typically caused by a break of the external blood vessels which can feel like a localized hardened marble-like area. This condition is known as a thrombosed external hemorrhoid.
- Long standing external hemorrhoids represent skin which has been stretched over time. It's a problem for some people since there is extra skin in the area which causes difficulty for proper hygiene
- Anal tears are one of the most common causes of anorectal pain at bowel movement, which can be quite severe and last for some time. Tears are often associated with repeated trauma, e.g., passage of a hard stool, but can also occur during bouts of diarrhea, childbirth, narrowing of the anal canal or ulceration of a hemorrhoid. If a tear does not heal, it becomes a fissure. The main reason tears do not heal and become fissures is due to inflammation from repeated trauma and coexisting contributing factors such as internal hemorrhoids. Therefore, fissures are usually caused by another issue which needs to be treated so the fissure itself will heal.
- vasoconstrictor inserted internally above the fissure which will treat the underlying condition and allow the fissure to heal.
- a physician prescribed vasodilator can be applied directly to the fissure to try and aid in healing by increasing blood flow directly to the fissure in conjunction with the aforementioned discussed vasoconstrictor.
- hemorrhoid treating products are available on the market today, but none are designed to provide enhanced effectiveness by targeting both internal and external disorders and by using any FDA approved active ingredient in combination with other ingredients which the FDA classifies as supplements to target specific contributing factors thereby enhancing the effectiveness of the treatment.
- Prior art is very specific to include External Use Only and is limited to FDA approved concentrations of Lidocaine as well as Phenylephrine and restrict a supplement to include Vitis vinifera (Grape) skin extract, aloe Barbadensis leaf juice extract, or Vitamin E.
- Prior art also requires an additional ingredient and list various ingredients some of which are commonly used as formulation “inactive” ingredients.
- Other ingredients include additional anorectal FDA active ingredients and two additional supplements, Eucalyptus oil and Ylang-ylang oil.
- the present invention is directed to a medicated treatment that contains FDA directed active ingredients within one of five categories as specified by the FDA either alone or in combination (as directed by the FDA).
- the FDA ingredients are then combined with ingredients in which the FDA classifies as “supplements” in order to enhance the overall effectiveness of the embodiment.
- Application of this treatment is designed to effectively reduce signs and symptoms of many anorectal disorders more effectively than either the FDA active ingredients or the supplements alone.
- the formulation of the present invention combines FDA approved therapies designed to treat specific signs and symptoms of anorectal disorders with supplements that specifically support and enhance the treatment of contributing factors.
- the FDA specifies treatments for anorectal disorders to include either alone or in combination the following:
- the FDA also specifies signs, symptoms and disorders which can be treated and what effect can be achieved using the approved ingredients. These include but are not totally inclusive of the following:
- the present invention relates to enhancing FDA approved topical treatments of anorectal disorders which include one to five categories of active ingredients being used alone or in combination as dictated in the anorectal monograph (specific reference presented elsewhere).
- the topical treatment can be used alone or in combination with other hemorrhoid treating devices and/or medications.
- the present invention relates to topical treatments of signs, symptoms of anorectal disorders and physiologic mechanisms causing or contributing to these factors. More specifically, the present invention relates to enhancing FDA approved topical treatments with supplements that specifically support and enhance the treatment of factors contributing or causing signs and symptoms of anorectal disorders and disease, some of which do not even have FDA approved treatments.
- FDA approved active ingredients are designed to treat include discomfort (including itching, pain, soreness, burning and relief from skin irritations), anorectal inflammation, swelling, abrasions and tears, and drying of inflamed tissues.
- Other factors causing anorectal signs and symptoms do not have specific FDA monograph approved treatments.
- the FDA does not provide for any products which have the potential to help heal or reduce bleeding. Examples of supplements which can used to treat these factors include:
- the present invention does address some or all the factors contributing to signs and symptoms in accordance with the anorectal monograph through combining FDA approved active ingredients with appropriate supplements which have been found to be scientifically effective in exhibiting an effect to help treat the factors contributing to signs and symptoms in accordance with the anorectal monograph, the FDA approved active ingredient reads, in part, as follows:
- Subpart B-Active Ingredients ⁇ 346.10 Local anesthetic active Ingredients.
- the active ingredient of the product consists of any of the following when used in the concentration or within the concentration range established for each ingredient: (a) Benzocaine 5 to 20 percent. (b) Benzyl alcohol 1 to 4 percent. (c) Dibucaine 0.25 to I percent. (d) Dibucaine hydrochloride 0.25 to 1 percent. (e) Dyclonine hydrochloride 0.5 to 1 percent. (f0 Lidocaine 2 to 5 percent. (g) Pramoxine hydrochloride 1 percent. (h) Tetracaine 0.5 to I percent. (i) Tetracaine hydrochloride 0.5 to 1 percent. ⁇ 346.12 Vasoconstrictor active Ingredients.
- the active ingredient of the product consists of any of the following when used in the concentration or within the concentration range established for each ingredient.
- the following active ingredients may be used as the sole protectant active ingredient in a product if the ingredient as identified constitutes 50 percent or more by weight of the final product.
- the following active ingredients may be used in concentrations of less than 50 percent by weight only when used in combinations in accordance with ⁇ 346.22 (a), (b), or (n).
- Aluminum hydroxide gel (2) Cocoa butter.
- Glycerin in a 20- to 45-percent (weight/weight) aqueous solution so that the final product contains not less than 10 and not more than 45 percent glycerin (weight/weight). Any. combination product containing glycerin must contain at least this minimum amount of glycerin.
- Hard fat (5) Kaolin. (6) Lanolin, (7) Mineral oil. (8) Petrolatum. (9) Topical starch. (10) White petrolatum.
- the following active ingredients may not be used as a sole protectant ingredient but may be used in combination with one, two, or three other protectant active ingredients in accordance with ⁇ 346.22 (a), (b), (n), and (o) and with the following limitations: (1) Calamine not to exceed 25 percent by weight per dosage unit (based on the zinc oxide content of calamine). (2) Cod liver oil, provided that the product is labeled .so that the amount of the product that is used in a 24-hour period represents a quantity that provides 10,000 U.S.P. units of vitamin A and 400 U.S.P. units of cholecalciferol.
- the active ingredient of the product consists of any of the following when used within the concentration range established for each ingredient: (a) Calamine, within a concentration range of 5 to 25 percent by weight per dosage unit (based on the zinc oxide content of calamine). (b) Hamamelis water, “The National Formulary XI,” 10 to 50 percent. (c) Zinc oxide, within a concentration range of 5 to 25 percent by weight per dosage unit. * 346.20 Keratolytic active Ingredients.
- the active ingredient of the product consists of any of the following when used within the concentration range established for each ingredient: (a) Alcloxa 0.2 to 2 percent. (b) Resorcinol 1 to 3 percent.
- any two, three, or four protectants identified in (a) ⁇ 346.14 may be combined, except aluminum hydroxide gel in ⁇ 346.14(a)(1) and kaolin in ⁇ 340.14(a)(5) may not be combined with any ingredient in ⁇ 346.14(a) (2), (4), (6), (7), (8) and (10), and (b) (2) and (3), provided that the combined percentage by weight of all protectants in the combination is at least 50 percent of the Federal Register/Vol. 55, No. 150/Friday, Aug. 3, 1990/Rules and Regulations final product (e.g., I gram of a 2-gram dosage unit).
- Any protectant ingredient included in the combination must be present at a level that contributes at least 12.5 percent by weight (e.g., 0.25 gram of a 2-gram dosage unit), except cod liver oil and shark liver oil. If an ingredient in I 346.14(b) is included in the combination, it must not exceed the concentration limit specified in ⁇ 346.14(b).
- Any single anorectal ingredient identified in ⁇ 348.10, 346.12. 346.16, 346.18, or 346.20 may be combined with up to four protectants in accordance with paragraph (a) of this section.
- Any single local anesthetic identified in ⁇ 346.10 may be combined with any single vasoconstrictor identified in ⁇ 346.12.
- Any single local anesthetic identified in 5 346.10 may be combined with any single astringent identified in ⁇ 346.18.
- Any single local anesthetic identified in ⁇ 346.10 may be combined with any single keratolytic identified in 1 346.20.
- Any single vasoconstrictor identified in ⁇ 346.12 may be combined with any single astringent identified in ⁇ 346.1.
- Any single analgesic, anesthetic, and antipruritic Identified in ⁇ 346.16 may be combined with any single astringent identified in ⁇ 346.18.
- Any single analgesic, anesthetic, and antipruritic identified in 1 346.16 may be combined with any single keratolytic identified in ⁇ 348.20.
- Any single astringent identified in ⁇ 346.18 may be combined with any single keratolytic identified in ⁇ 346.20.
- Any single local anesthetic identified in 1 346.10 may be combined with any single vasoconstrictor identified in ⁇ 346.12 and with any single astringent Identified in ⁇ 346.18.
- Any single local anesthetic identified in ⁇ 346.10 may be combined with any single astringent Identified in ⁇ 346.18 and with any single keratolytic identified in ⁇ 346.20.
- Any single vasoconstrictor identified in 1 346.12 may be combined with any single analgesic, anesthetic. and antipruritic identified in ⁇ 346.18 and with any single astringent identified in ⁇ 346.18.
- Any single analgesic, anesthetic, and antipruritic identified in ⁇ 348.16 may be combined with any single astringent identified in 1 346.18 and with any single keratolytic identified in 9 346.20.
- Any combination of ingredients listed in paragraphs (c) through (in) of this section may be combined with up to four protectants in accordance with paragraph (a) of this section.
- Any product containing calamine for use as a protectant and/or as an astringent and/or containing zinc oxide for use as a protectant and/or as an astringent may not have a total weight of zinc oxide exceeding 25 percent by weight per dosage unit.
- a composition including: at least one U.S. Food & Drug Administration (FDA) approved anorectal active ingredient; and at least one supplement which exhibits an activity as defined under the following categories: exhibit activity against inflammation; exhibit activity against irritation contributing to discomfort and bleeding; exhibit a calming or soothing effect; designed to reduce muscle spasm; antimicrobials that are either a direct cause of inflammation or part of the inflammatory process; dispersion agents; wound healing supplements; pain relieving supplements; and supplements which provide vascular support.
- FDA U.S. Food & Drug Administration
- a cushioned seat for relieving tailbone and hemorrhoid pain including the following: a seat cushion dimensioned to accommodate a human sitter centered over a central section; an operative contoured surface provided along an upward-facing portion of the seat cushion, the operative contoured surface providing: a rear contour having a first elevation at both longitudinal edges and a rear edge; the first elevation being greater than other elevations of the rear contour; the rear contour slopes downward longitudinally until a transition area; both longitudinal edges sloping downward laterally toward each other and until a medial contour; the transition area sloping upwardly as it extends away from the rear contour to a lateral contour; the thing contour cresting at a second elevation and sloping downwardly to a forward contour; and the second elevation being greater than the first elevation, whereby the lateral contour raises a posterior thigh of the human sitter allowing associated buttocks and external hemorrhoids vessels to be in direct contact with the central section.
- FIG. 1 is a perspective view of an exemplary embodiment of the present invention
- FIG. 2 is a top view of an exemplary embodiment of the present invention, demonstrating use of a cooling pack
- FIG. 3 is a perspective view of an exemplary embodiment of the present invention.
- FIG. 4 is a side perspective view of an exemplary embodiment of the present invention, shown positioned on a seat.
- the present invention uses “supplements” to create “enhanced” effectiveness by treating pathophysiology from a multidisciplined approach.
- supplies may include supplements from one or in combination with any or all the following:
- the present invention is described in the general context of compositions for treating hemorrhoids and conditions related to hemorrhoids as well. This includes but is not limited to anal fissures, piles, proctitis, proctospasm, abscesses, fistulas and related conditions. Additionally, such embodiments can be used to relieve or reduce pre- and post-surgical anorectal symptoms and potentially aid in healing (per scientific references on wound healing supplements if contained in one of the embodiments of the present invention).
- treatment refers to the medical management of a patient with the intent to cure, ameliorate, stabilize, or prevent a hemorrhoids and related conditions or disorders.
- This term includes active treatment, that is, treatment directed specifically toward the improvement of hemorrhoids and related conditions and includes palliative treatment, that is, treatment designed for the relief of symptoms rather than the curing of hemorrhoids and related conditions.
- the term “alleviate” or “alleviating” refers to lightening or lessening the severity of a symptom, condition, or outbreak of hemorrhoids and related conditions.
- a treatment that reduces the severity of pain in a subject can be said to alleviate pain.
- the term “effective amount” refers to an amount that is sufficient to achieve the desired result or to have an effect on an undesired condition.
- a “therapeutically effective amount” refers to an amount that is sufficient to achieve the desired therapeutic result or to have an effect on undesired symptoms associated with hemorrhoids and related conditions but is generally insufficient to cause adverse side-affects.
- the specific therapeutically effective dose level for any particular patient will depend upon a variety of factors including the severity of the hemorrhoids and related conditions; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed and like factors well known in the medical arts.
- aqueous and nonaqueous carriers refers to sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, for reconstitution into steriletopical ointments and/or creams.
- suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, methanol, isopropanol, polyols (such as glycerol, propylene glycol, polyethylene glycol and the like), carboxymethylcellulose and suitable mixtures thereof, vegetable oils (such as olive oil, light mineral oil, cottonseed oil, castor oil, and the like) and injectable organic esters such as ethyl oleate.
- Proper fluidity can be maintained, for example, by the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants.
- salts refers to a salt prepared from a base or acid that is acceptable for administration to a patient, such as a mammal.
- Such salts can be derived from pharmaceutically acceptable inorganic or organic bases and from pharmaceutically acceptable inorganic or organic acids.
- Salts derived from pharmaceutically acceptable inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic, manganous, potassium, sodium, zinc and the like. Particularly preferred are ammonium, calcium, magnesium, potassium and sodium salts.
- Salts derived from pharmaceutically acceptable organic bases include salts of primary, secondary and tertiary amines, including substituted amines, cyclic amines, naturally-occurring amines and the like, such as arginine, betaine, caffeine, choline, N,N′-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperadine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine and the like.
- arginine betaine
- caffeine choline
- Salts derived from pharmaceutically acceptable acids include acetic, ascorbic, benzenesulfonic, benzoic, camphosulfonic, citric, ethanesulfonic, fumaric, gluconic, glucoronic, glutamic, hippuric, hydrobromic, hydrochloric, isethionic, lactic, lactobionic, maple, malic, mandelic, methanesulfonic, mucic, naphthalenesulfonic, nicotinic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric (providing a tartrate or bitartrate), p-toluenesulfonic and the like.
- Particularly preferred are citric, hydrobromic, hydrochloric, maple, phosphoric, sulfuric and tartaric acids.
- anorectal disease Painful conditions of the anal region”, “anal conditions”, “anal pain”, and the like, are used herein to describe symptoms of discomfort or pain in a person's anorectal area, or the diseases and disorders that produce them.
- Anorectal diseases include anal fissures, thrombosed or inflamed hemorrhoids, pain associated with the aftereffects of anal surgery and procedures (such as rubber-band ligation of internal hemorrhoids) and chronic anal pain.
- the anorectal area comprises the anal mucosa, the mucosa of the most distal portion of the rectum, the internal and external anal sphincters, the skin immediately surrounding the anus.
- FDA Classification “Active agent” or “Active ingredient”, as used herein, refers to any component in a composition of the present invention that has been approved for use in anorectal disorders by the FDA (and referenced in the anorectal monograph) because of their known ability to reduce the symptoms associated with anorectal disease.
- “Supplements” differ from “active agent” or “Active ingredient”, as used herein, to mean any component that can be added to a composition that has some biological effect according to a consensus of reference guides on supplements, whether the biological effect is directly related to anorectal disease or not.
- the biological effect is preferably curative.
- Such components might have analgesic or anesthetic effects,
- Such components might alternatively have an activity unrelated to pain reduction such as anti-inflammatory effect, muscle relaxing effects, vascular support effects, calming effects, improved dispersion, and anti-microbial effects as examples.
- Xylocaine has the generic name lidocaine and may be used as an active ingredient of the composition of the present invention (other FDA approved anesthetics may also be used and are listed in the anorectal monograph).
- Lidocaine is an intermediate-duration anesthetic, that is incorporated into the gel, lotion, paste, wipe or solution of the present invention and can be safely applied within an effective dosage protocol topically usually every 3-4 hours to obtain relief of pain. If used, the FDA specified concentration ranges from as low as 2% to as high as 5%.
- Lidocaine is a local anesthetic and antiarrhythmic drug. Lidocaine is used topically to relieve itching, burning and pain from skin inflammations that is often associated with hemorrhoids and related conditions.
- the topical treatment of the present invention may consist of a single application of a treatment containing concentrations of phenylephrine HCl and lidocaine permitted by the Food and Drug Administration (FDA) in combination with a supplement which is sufficient for some outbreaks of an anorectal condition but most cases require multiple applications.
- FDA Food and Drug Administration
- compositions of the present invention can also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganism contamination can be ensured by the inclusion of various antibacterial and antifungal agents such as glycerin, capryl hydroxamic acid, paraben, chlorobutanol, phenol, sorbic acid, chlorohexidine digluconate, and the like. Antioxidants, such as BHT, can be included. It can also be desirable to include isotonic agents such as sugars, sodium chloride and the like.
- any conventional adjuvants can be used in the present composition.
- antioxidants for example sodium or potassium metabisulfite
- isotonic agents such as sodium chloride
- chelating agents such as EDTA or citric acid
- pH adjustment agents such HCl or NaOH, present in an amount desirable to achieve a pH of, for example, from 3.3-5.5
- minor impurities such as aluminum salts
- other ingredients include opiates, such as morphine and fentanyl (used to provide epidural/spinal anesthesia); NMDA antagonists, such as dextromethorphan; clonidine; antiinflammatory agents; antibiotics; and the like.
- the active ingredient is customarily diluted by an excipient.
- suitable excipients include water, sterile saline, syrup, and methylcellulose.
- the formulations can additionally include emulsifying and suspending agents; preserving agents, such as methyl- and propylhydroxy-benzoates; and flavoring and coloring agents.
- the compounds of this invention may be formulated using conventional techniques such as those described in Remington's Pharmaceutical Sciences, Mace Publishing Co., Philadelphia, Pa. 17th Ed. (1985) and “Modern Pharmaceutics,” Marcel Dekker, Inc. 3.sup.rd Ed. (G. S. Banker & C. T. Rhodes, Eds.).
- Pharmaceutically acceptable salts of the active agents e.g., acid addition salts
- the composition designed to treat hemorrhoids and related conditions comprises what the FDA recognizes as a therapeutic effective amount of phenylephrine HCl (or other FDA approved vasoconstrictor) for relieving swelling caused by hemorrhoids and related conditions.
- Phenylephrine HCl is an active ingredient of the ointment that acts to shrink the swollen tissues associated with hemorrhoids by constricting blood vessels that feed blood and fluid to the area around the hemorrhoid.
- Phenylephrine HCl is a ⁇ -adrenergic receptor agonist that binds to ⁇ -adrenergic receptors that once activated set off a physiological process in the body that restricts blood supply to the area of the hemorrhoids and thereby reduces swelling in this area.
- the favorable effects of phenylephrine HCl on hemorrhoids are often masked by the itching and pain in the area around the hemorrhoid(s).
- the present invention may also include lidocaine, or any other FDA monograph approved analgesic, anesthetic, antipruritic or astringent ingredient.
- supplements are added to the topical treatment. These supplements can be used alone, in combination with other supplements which exhibit similar characteristics, or with supplements which exhibit different characteristics many of which can be described below. Examples of references supporting the use of supplements for these indications include:
- Camellia sinensis also known as tea tree
- Clinical trials have proven the efficacy of preparations made from many supplements such as horse chestnut and Gotu Cola as examples in the treatment of venous insufficiency. These effects have been in reducing significantly lower leg edema and circumference whilst improving other chronic symptoms to a clinically relevant extent. This relates to increased pressure typically found in hemorrhoid disease in which such reduction of pressure can effectively reduce or resolve prolapsing or protruding hemorrhoids.
- Camellia sinensis contain a wide range of polyphenol flavonoids including flavon (op-glycosides and glucuronides, quercetin-3-O-beta-D-glucuronide (main flavonoid), isoquercitrin, anthocyanins, oligomeric proanthocyanidins, catechin, epicatechin monomers and dimers; gallic acid and astilbine.
- Turmeric as another example reduces swelling and compliments the active ingredient phenylephrine HCl. The proposed mechanism of action by which Turmeric (curcumin) induces its anti-inflammatory effects is yet to be fully elucidated.
- PPAR- ⁇ peroxisome proliferator-activated receptor gamma
- PPARs belong to the superfamily of nuclear receptors consisting of three genes that give rise to three different subtypes, PPAR- ⁇ , PPAR- ⁇ , and PPAR- ⁇ .
- PPAR- ⁇ is the most widely studied form.
- PPAR- ⁇ forms heterodimers with the retinoid X receptor and binds to a peroxisome proliferation response element (PPRE) in a gene promoter leading to regulation of gene transcription.
- PPRE peroxisome proliferation response element
- gene and protein levels of PPAR- ⁇ in the liver decreased by approximately 50% at 20 hours after the onset of sepsis.
- Pretreatment with curcumin for 3 days at 0.24 ⁇ mol/kg body weight in these septic rats produced 45% and 65% increase in PPAR- ⁇ mRNA and protein levels, respectively.
- the topical treatment of the present invention may also include Lavender Oil.
- Lavender Oil is another example of a supplemental ingredient that complements the active ingredients of the present invention. This is effective in further reducing inching and soothing the area around the hemorrhoid(s). Punica granatum is an astringent that helps to heal open wounds and therefore aids in reducing bleeding and itching often associated with hemorrhoids and related conditions.
- the topical treatment of the present invention combines both conventional medical compositions such as phenylephrine HCl and lidocaine with supplemental compositions such as horse chestnut, chamomile, etc. to produce a topical treatment that is more potent for treating hemorrhoids and related conditions than other topical treatments that use conventional ingredient or supplemental ingredients alone.
- such treatments may provide effects which are not able to be achieved using traditional FDA approved active ingredients.
- the overlapping of ingredients that has cumulative and complementary affects aids in prolonging the therapeutic effects of the claimed topical treatment as compared to other topical treatments for treating anorectal disorders available on the market today. That is, the claimed topical treatment enhances this by adding additional ingredients beyond what the FDA provides for and considers “active” in the anorectal monograph.
- These supplemental ingredients enhance the potency of the claimed topical treatment as well as extend the duration of effectiveness.
- compositions of the present invention are typically administered in a therapeutically effective amount. It will be understood, however, that the amount of the compound administered will be determined by the FDA dosing recommendations governing the active drug ingredients.
- the treatment comprises 4% to 5% by weight of lidocaine and 0.25% by weight of phenylephrine HCl as active ingredients and algae extract, chamomile, Ginseng, and Sodium Hyaluronate as supplemental ingredients.
- the topical treatment may also be comprised of additional or different active ingredients as well as different supplemental ingredients and combined with non-active components including benzyl alcohol, carbomer, cholesterol, hydrogenated lecithin, isopropyl myristate glycol, triethanolamine, Vitamin E Acetate, and purified water, fragrances, coloring agents, vitamins, oils, stability agents and/or other ingredients necessary to maintain the effectiveness of the topical treatment.
- the carbomer polymers of the ointment are used as thickening, dispersing, and emulsifying agents. They are also used to control the release of medicaments from time-release tablets or from entrapped systems.
- Carbomers are largely insoluble in water and in the majority of common solvents. When neutralized (with bases, e.g., hydroxides or amines), Carbomers can be soluble in water, alcohol and glycerin. Carbomers are hygroscopic in nature, swelling to many times their original volume when in contact with a solvent. Such swollen particles remain discrete in various mucilaginous or colloidal dispersions.
- maximum volume swell does not typically occur in water until the polymers are converted to partial organic or inorganic salts.
- the increased volume is generally stable at all pH levels but increases as neutralization increases.
- Maximum volume occurs at 50-90% neutralization, with a neutralization of 75% normally occurring at pH 7.0.
- the topical treatment composition of the present invention is made by mixing the active ingredients and supplemental ingredients into a pharmaceutically acceptable carrier and adding the other ingredients as well as water in an order that provides a topical cream, ointment, lotion, gel, spray, suppository, wipe etc. wherein the activity of the conventional and supplemental ingredients are maintained.
- Conventional producing procedures used in the art can also be used to make the desired composition of the present invention.
- one method that can be used to produce the water-based topical ointment of the present invention includes the steps of: providing a mixture of aqueous solvent, one or more penetration enhancers, and, optionally, one or more preservatives; adding to the mixture one or more thickeners; adding to the mixture one or more emulsifiers; heating the mixture to at least a temperature sufficient to solubilize or melt the one or more thickeners and/or one or more emulsifiers; adding phenylephrine HCL and lidocaine as well as the supplemental ingredients; and adjusting the pH of the mixture to from about 4 to about 6 with a pH-adjuster.
- the pH is adjusted before or during one or more of the providing, adding, and heating steps. In a yet further aspect, the pH is adjusted after the providing, adding, and heating steps.
- the ointment comprises at least about 60% aqueous solvent by weight.
- the mixture is provided as a uniform suspension (dispersion) of ingredients. In certain aspects, the mixture can appear as an emulsion or a solution. It is understood that this method is just one method that can be used to make the ointment of the present invention but other methods available in the art can also be used.
- topical treatment composition Once the topical treatment composition is produced it can be provided in a single dosage convenient packaging, a squeezable tube, a wide-mouth jar, saturated on a pad for application, suppository sheet, or any other suitable storage means.
- compositions of the disclosed invention can be provided in a form suitable for topical use such as, for example, cream, ointment, lotion, gels and the like. Further, the compositions can be in a form suitable for use in transdermal devices as well such as wipes, clothes, applicators, pads, and other applications including specifically designed under garments that are designed to keep the ointment in place. All these formulations can be prepared via conventional processing methods as discussed above.
- composition can be used with many specific anal conditions including but not limited to hemorrhoids, anal fissures, anal tears, anal scarring and the like.
- topical treatment of the present invention can be included as part of a kit that contains a hemorrhoid reducing/comfort seat as well as instructions for using the seat and applying the topical treatment thereafter.
- the present invention includes a specialized foam comfort cushion with a mesh pocket to hold a cold or hot gel insert or electric heating pad.
- This cushion can be sat on comfortably and the gel insert will provide direct cold or heat as desired to the external hemorrhoidal cushions.
- Cold therapy has been found to reduce inflammation, swelling and soreness. Cold is typically recommended as an anti-inflammatory during the first 24 hours of injury as an example in the case of a ruptured external hemorrhoid blood vessel causing an external thrombotic hemorrhoid. Heat therapy can help relieve discomfort by providing a warm, comforting sensation. Heat also helps increase blood flow throughout the body. Increased blood flow can heal injuries faster. In the case of a thrombosed external hemorrhoid as an example, heat is advised after 24 hours to improve vascular circulation thereby allowing improved blood flow and drainage thereby allowing reabsorption of the clot(s).
- the present invention is also directed to the method of treating hemorrhoids and related conditions by applying the topical treatment of the present invention either alone or in combination with the use of a cushion device designed to provide comfort while applying heat or cold directly to the perianal location so as to alleviate discomfort, reduce swelling, improve healing or as an example, cause an external thrombosis to be reabsorbed by the body.
- a cushion device designed to provide comfort while applying heat or cold directly to the perianal location so as to alleviate discomfort, reduce swelling, improve healing or as an example, cause an external thrombosis to be reabsorbed by the body.
- the topical treatment of the present invention is designed to reduce these symptoms as discussed above.
- the present invention may include a sitting cushion integrating heating and cooling elements and adapted in shape to relieve tailbone and hemorrhoid pain.
- the uniquely adapted treatment seat integrates hot or cold pads into a sitting cushion for providing significant enhanced pain relief and comfort.
- the present invention “solves the problem” of providing both a comfortable surface to sit on while applying heat or cold to relieve lower back, tailbone and hemorrhoid discomfort.
- the present invention includes a seat portion 10 providing a storage space 12 for removably retaining heating-cooling elements 18 .
- the seat portion 10 may be a sitting cushion having a uniquely shaped operative contoured surface 16 .
- the storage space 12 may be a mesh pocket applied to cushion sewed or adhered using adhesive material sitting cushion.
- the heating-cooling elements 18 may be gel pad which can be cooled in freezer and/or heated in a microwave and slid into an opening 14 of the pocket/compartment 12 .
- a method of manufacturing the present invention may include, the following.
- a manufacturer may first cut the mesh pocket in a size and shape to assure coverage of the affected areas designed to be treated by the apparatus, mainly the tailbone, lower back and external hemorrhoid (peri-anal) regions. This area can vary in size and shape as long as it provides coverage for the affected regions.
- the mesh pocket may be attached to the sitting cushion by way of sewing or any chemical adhesion method.
- a gel pad may be used which will fit into the mesh pocket and be large enough to provide coverage for the affected area. The gel pad may be either heated or cooled and subsequently to being placed into the mesh pocket.
- the manufacturer may start from a generic sitting cushion, attach the mesh pocket to the sitting cushion and place a gel pad which has been heated in a microwave (or other generic heating apparatus) or cooled in the freezer (or other cooling apparatus).
- the pocket and pad must be measured to provide coverage to the tailbone, lower back and perianal (hemorrhoid) region.
- the contours the operative contoured surface 16 are dimensioned and adapted so that when the user arrives at the appropriate size, the pocket 12 and temperature element 18 are cut to the appropriate size and the pocket (or electrical stimulation pad) is attached to the sitting cushion 10 using adhesives or stitching.
- the back of the operative contoured surface 16 may have a slight raised area to able to rest the lower back while helping to provide a guide so that the subject is correctly positioned on the operative contoured surface 16 of the cushion 10 .
- a lateral contour may raise posterior thigh allowing buttocks and specifically lower spine and external hemorrhoids vessels to be in direct contact with the heating-cooling element 18 .
- the lateral contour may achieve a maximum elevation (relative to the bottom surface) approximately eight inches from the rear of the seat portion 10 and then slope continuously downward in a forward direction.
- the seat portion 10 may provide an elevated posterior thigh causing flexion at the hip, when the present invention is placed on a seat 20 with the operative contoured surface 16 upward-facing.
- the operative contoured surface 16 provides an angled support surface (due to the angle of inclination of the surfaces) including a pair of spaced apart thigh contours 30 defining an anorectal portion 40 dimensioned and adapted accommodate a human sitters anorectal/anus when seated on the operative contoured surface 16 .
- Thigh contours 30 are concave shapes configured to spread the sitter's thighs so as to evenly distribute pressure from the anorectal portion 40 onto the anorectal/anus of the sitter.
- the anorectal portion 40 is where the heating-cooling element 18 is disposed so as to be urged against the ‘spread’ anus of the sitter.
- the temperature adaptive element may be a “hot or cold” gel insert. Heat is better for enhanced relaxation and increased circulation related to anorectal disorders associated with muscle spasm, anal fissures as an example as well as external thrombotic hemorrhoids since the heat will help to dissolve the clots. Cold as discussed elsewhere, aids in reducing inflammation and works best to alleviate pain.
- an electrical stimulation device to the area currently designed to contain the mesh pocket and gel pad. Attaching an electrical stimulation device to a sitting cushion (in the area currently designed to contain the mesh pocket and gel pad) would also allow relief of low back, tailbone and hemorrhoid pain and discomfort.
- the apparatus would differ by applying an electrical stimulation pad instead of a pocketed gel pad—i.e., relief would be accomplished by using muscle stimulation verses temperature-initiated relief based on cold (anesthesia and anti-inflammatory) or heat (soothing and improved circulatory response).
- the integrated element 24 of the alternative embodiment 22 could be integrated along the operative contoured surface 16 of the therapeutic cushion 10 .
- compositions, ointments, gel, lotions, foam and mixtures and combinations thereof most likely will require at least one topical carrier selected from the group consisting of creams, ointments, gel, lotions, foam and mixtures and combinations thereof, wherein said composition is designed for internal and or external topical use and application, and said composition is designed to relieve one or all of the following: swelling, burning, pain and itching, irritation, inflammation, protrusion as well as protect inflamed and or irritated tissues, or provide a cooling sensation to the various signs and symptoms caused by various disorders afflicting the anus and rectum.
- topical carrier selected from the group consisting of creams, ointments, gel, lotions, foam and mixtures and combinations thereof, wherein said composition is designed for internal and or external topical use and application, and said composition is designed to relieve one or all of the following: swelling, burning, pain and itching, irritation, inflammation, protrusion as well as protect inflamed and or irritated tissues, or provide a cooling sensation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Engineering & Computer Science (AREA)
- Nursing (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A topical treatment for anorectal disorders with and without utilization of a contoured seat cushion with a temperature-adapted or electrical stimulation element that can provide hot or cold temperatures or electrical stimulation to the anorectal region.
Description
- This application claims the benefit of priority of U.S. provisional application No. 62/796,194, filed 24 Jan. 2019, and as a divisional of U.S. non-provisional application Ser. No. 16/750,372, filed 23 Jan. 2020, the contents of which are herein incorporated by reference.
- The present invention relates to medical treatments for anorectal disorders and, more particularly, to a topical treatment for anorectal disorders with and without seat cushion; specifically, internal and externally applied topical products (ointments, creams, lotions, suppositories, gels, wipes, etc.) which aid in relieving or protecting from various symptoms of anorectal disease or disorders such as burning, itching, irritation, pain or mild inflammation of the skin or mucous membranes associated with various anorectal disorders which may include but not to be inclusive of internal and external hemorrhoids, anal fissures, proctitis, cryptitis and the method of using such topical treatments, as well as using a contoured seat cushion with a temperature adaptive insert gel or electrothermal heat pad insert.
- Hemorrhoids are one of the most common causes of anorectal pathology. Subsequently, hemorrhoids are blamed for virtually any anorectal complaint by patients and medical professionals alike even though there are other distinct or contributing disorders such as anal fissures, proctitis, cryptitis, etc. Confusion often arises because the term “hemorrhoid” has been used to refer to both normal anatomical structures and pathological structures. In the context of this application, “hemorrhoids” refers to the pathological presentation of hemorrhoidal venous cushions.
- Hemorrhoidal venous cushions are normal structures of the anorectum and are universally present unless a prior surgical intervention has taken place. Because of their rich vascular supply, highly sensitive location, and tendency to engorge and prolapse, they are common causes of anal pathology. Symptoms can range from mildly bothersome, such as itching with is referred to as pruritus, to quite concerning, such as rectal bleeding. While it is a common condition diagnosed in clinical practice, many patients are too embarrassed to ever seek treatment. Consequently, the true prevalence of pathologic hemorrhoids is not known.
- Hemorrhoidal venous cushions are a normal part of the human anorectum and arise from subepithelial connective tissue within the anal canal. Present in utero, these cushions surround and support distal anastomoses between the superior rectal arteries and the superior, middle, and inferior rectal veins. They also contain a subepithelial smooth muscle layer, contributing to the bulk of the cushions. Normal hemorrhoidal tissue accounts for approximately 15-20% of resting anal pressure and provides important sensory information, enabling the differentiation between solid, liquid, and gas.
- Most people anatomically possess three main cushions. Although classically described as lying in the right posterior (most common), right anterior, and left lateral positions, this combination is found in only 19% of patients. Hemorrhoids can be found at any position within the rectum.
- Hemorrhoids are classified by their anatomic origin within the anal canal and by their position relative to the dentate line. The dentate line is between the simple columnar epithelium of the rectum and the stratified epithelium of the anal canal. Internal hemorrhoids develop above the dentate line from embryonic endoderm. They are covered by the simple columnar epithelium of anal mucosa and lack typical somatic sensory innervation. Therefore, people who have swollen or inflamed internal hemorrhoids in isolation without coexisting pathology do not contribute to the majority of people who suffer from anorectal pain as their primary symptom.
- External hemorrhoids develop from ectoderm and arise distal to the dentate line. They are covered by stratified squamous epithelium and receive somatic sensory innervation from the inferior rectal nerve rendering them painful when irritated, painful, swollen or thrombosed.
- Mixed hemorrhoids are confluent internal and external hemorrhoids. Internal hemorrhoids drain through the superior rectal vein into the portal system. External hemorrhoids drain through the inferior rectal vein into the inferior vena cava. Rich anastomoses exist between these two and the middle rectal vein, connecting the portal and systemic circulations. It is for this reason that symptomatic external hemorrhoids can never exist without internal hemorrhoids as a contributing factor.
- Hemorrhoids usually are not dangerous or life threatening. Very rarely, a patient can have bleeding so severe, that severe anemia or death may occur. In some cases, hemorrhoidal symptoms simply go away within a few days. But in most cases, hemorrhoidal symptoms eventually return, often worse than they were previously. The most common symptom of internal hemorrhoids is bright red blood covering the stool, on toilet paper, or in the toilet bowl. However, an internal hemorrhoid may protrude through the anus outside the body, becoming irritated and painful. This is known as a protruding or prolapsing internal hemorrhoid. Sudden external swelling is typically caused by a break of the external blood vessels which can feel like a localized hardened marble-like area. This condition is known as a thrombosed external hemorrhoid. Long standing external hemorrhoids represent skin which has been stretched over time. It's a problem for some people since there is extra skin in the area which causes difficulty for proper hygiene.
- In addition, excessive straining, rubbing, or cleaning around the anus may cause irritation with bleeding and/or itching, which may produce a vicious cycle of symptoms.
- Anal tears (fissures) are one of the most common causes of anorectal pain at bowel movement, which can be quite severe and last for some time. Tears are often associated with repeated trauma, e.g., passage of a hard stool, but can also occur during bouts of diarrhea, childbirth, narrowing of the anal canal or ulceration of a hemorrhoid. If a tear does not heal, it becomes a fissure. The main reason tears do not heal and become fissures is due to inflammation from repeated trauma and coexisting contributing factors such as internal hemorrhoids. Therefore, fissures are usually caused by another issue which needs to be treated so the fissure itself will heal. Many times, the cause of the fissure will require a vasoconstrictor inserted internally above the fissure which will treat the underlying condition and allow the fissure to heal. In difficult cases, a physician prescribed vasodilator can be applied directly to the fissure to try and aid in healing by increasing blood flow directly to the fissure in conjunction with the aforementioned discussed vasoconstrictor.
- A number of hemorrhoid treating products are available on the market today, but none are designed to provide enhanced effectiveness by targeting both internal and external disorders and by using any FDA approved active ingredient in combination with other ingredients which the FDA classifies as supplements to target specific contributing factors thereby enhancing the effectiveness of the treatment.
- Prior art is very specific to include External Use Only and is limited to FDA approved concentrations of Lidocaine as well as Phenylephrine and restrict a supplement to include Vitis vinifera (Grape) skin extract, aloe Barbadensis leaf juice extract, or Vitamin E. Prior art also requires an additional ingredient and list various ingredients some of which are commonly used as formulation “inactive” ingredients. Other ingredients include additional anorectal FDA active ingredients and two additional supplements, Eucalyptus oil and Ylang-ylang oil. In fact, some prior art refers to their required supplemental additional ingredients (Vitis vinifera (Grape) skin extract, aloe Barbadensis leaf juice extract, or Vitamin E, Eucalyptus oil and Ylang-ylang oil) as “homeopathic” which is incorrect.
- In summary, prior art specify ingredients that must be included:
-
- a. Lidocaine
- b. Phenylephrine
- c. Vitis vinifera (Grape) skin extract, aloe Barbadensis leaf juice extract, or Vitamin E
- d. at least one FDA approved astringent
- e. at least one FDA approved protective
- f. at least one topical carrier
- g. External Use Only
- And specify which may include the following additional supplements:
-
- a. Eucalyptus oil and Ylang-ylang oil
- And specify ingredients or applications which must NOT include:
-
- a. glycerin,
- b. internal application
- There is an obvious need for medicated topical treatments that work more efficiently and effectively to reduce and relieve anorectal symptoms as well as the cause of these symptoms. An example would be a product which not only shrinks the hemorrhoid but also delivers immediate relief to the pain and itching, and other symptoms often associated with this and other anorectal conditions. Additionally, more often than not, swelling causes inflammation which can significantly worsen the signs and symptoms as well as the condition itself. Muscle spasm has also been frequently associated with anorectal pain and discomfort causing more pain with bowel movements and even causing bowel motility issues. Other causes of inflammation not related to hemorrhoids include proctitis of unknown etiology, various microbial infestations and bowel disorders.
- The present invention is directed to a medicated treatment that contains FDA directed active ingredients within one of five categories as specified by the FDA either alone or in combination (as directed by the FDA). The FDA ingredients are then combined with ingredients in which the FDA classifies as “supplements” in order to enhance the overall effectiveness of the embodiment. Application of this treatment is designed to effectively reduce signs and symptoms of many anorectal disorders more effectively than either the FDA active ingredients or the supplements alone.
- The formulation of the present invention combines FDA approved therapies designed to treat specific signs and symptoms of anorectal disorders with supplements that specifically support and enhance the treatment of contributing factors.
- The FDA specifies treatments for anorectal disorders to include either alone or in combination the following:
-
- a. Local Anesthetic active ingredients
- b. Protectant active ingredients
- c. Vasoconstrictor active ingredients
- d. Astringent active ingredients
- e. Analgesic, anesthetic and antipruritic active ingredients
- f. Keratolytic active ingredients
- The FDA also specifies signs, symptoms and disorders which can be treated and what effect can be achieved using the approved ingredients. These include but are not totally inclusive of the following:
-
- a. Discomfort (including itching, pain, soreness, burning and relief from skin irritations)
- b. Anorectal Disorders (including hemorrhoids and other disorders)
- c. Anorectal Inflammation
- d. Swelling
- e. Protects irritated areas, inflamed anorectal surfaces and perianal skin and abrasions
- f. Forms a protective coating over inflamed tissues to help prevent drying
- g. Provide a cooling sensation
- In sum, the present invention relates to enhancing FDA approved topical treatments of anorectal disorders which include one to five categories of active ingredients being used alone or in combination as dictated in the anorectal monograph (specific reference presented elsewhere). The topical treatment can be used alone or in combination with other hemorrhoid treating devices and/or medications.
- The present invention relates to topical treatments of signs, symptoms of anorectal disorders and physiologic mechanisms causing or contributing to these factors. More specifically, the present invention relates to enhancing FDA approved topical treatments with supplements that specifically support and enhance the treatment of factors contributing or causing signs and symptoms of anorectal disorders and disease, some of which do not even have FDA approved treatments.
- The most common factors FDA approved active ingredients are designed to treat include discomfort (including itching, pain, soreness, burning and relief from skin irritations), anorectal inflammation, swelling, abrasions and tears, and drying of inflamed tissues. Other factors causing anorectal signs and symptoms (such as proctospasm), do not have specific FDA monograph approved treatments. In fact, the FDA does not provide for any products which have the potential to help heal or reduce bleeding. Examples of supplements which can used to treat these factors include:
-
- Horse Chestnut (vascular support and reduction of swelling)
- Algae Extract (antiviral contributors to inflammation)
- Calendula Extract (wound healing)
- Chamomile (reduces inflammation)
- Lysine (antiviral contributors to inflammation)
- Ginseng Root (reduces spasm)
- Pomegranate (astringent)
- Gotu Kola (vascular support and reduction of swelling)
- Argan Oil (antibacterial, anti-inflammatory and antioxidant action)
- Camellia sinensis Tea Plant (astringent)
- Coconut Oil (pain relieving)
- Turmeric (anti-inflammatory)
- Candelilla Wax (protective barrier)
- Lavender Oil (calming reduction of irritation, wound healing)
- Linseed Oil (calming reduction of irritation and inflammation)
- Olive Oil (antimicrobial, moisturizing)
- Macadamia Oil (wound healing, moisturizing)
- Avocado Oil (reduction of inflammation, wound healing, moisturizing)
- Patchouli Oil (calms, moisturizes, anti-inflammatory, wound healing)
- Castor Seed Oil (calms, moisturizes, anti-microbial)
- Rose Hip Oil (moisturizes, anti-inflammatory)
- Hyaluronate (improves absorption by enhancing dispersion of ingredients)
- Cramp Bark (reduces spasm)
The present invention differs from the prior art for the following reasons: - 1. The present invention does not specify for the use of any specific anorectal FDA drug category
- 2. The present invention does not specify for a combination of anorectal FDA drug categories
- 3. The present invention does not restrict supplements to include Vitis vinifera (Grape) skin extract, aloe Barbadensis leaf juice extract, and/or Vitamin E, Eucalyptus oil and Ylang-ylang oil
- 4. The present invention does not restrict the use of Glycerin
- 5. The present invention does specify external use only
- The present invention does address some or all the factors contributing to signs and symptoms in accordance with the anorectal monograph through combining FDA approved active ingredients with appropriate supplements which have been found to be scientifically effective in exhibiting an effect to help treat the factors contributing to signs and symptoms in accordance with the anorectal monograph, the FDA approved active ingredient reads, in part, as follows:
- Subpart B-Active Ingredients § 346.10 Local anesthetic active Ingredients. The active ingredient of the product consists of any of the following when used in the concentration or within the concentration range established for each ingredient: (a) Benzocaine 5 to 20 percent. (b) Benzyl alcohol 1 to 4 percent. (c) Dibucaine 0.25 to I percent. (d) Dibucaine hydrochloride 0.25 to 1 percent. (e) Dyclonine hydrochloride 0.5 to 1 percent. (f0 Lidocaine 2 to 5 percent. (g) Pramoxine hydrochloride 1 percent. (h) Tetracaine 0.5 to I percent. (i) Tetracaine hydrochloride 0.5 to 1 percent. § 346.12 Vasoconstrictor active Ingredients. The active ingredient of the product consists of any of the following when used in the concentration or within the concentration range established for each ingredient. (a) Ephedrine sulfate 0.1 to 1.25 percent. (b) Epinephrine 0.005 to 0.01 percent. (c) Epinephrine hydrochloride 0.005 to 0.01 percent. (d) Phenylephrine hydrochloride 0.25 percent. § 346.14 Protectant active Ingredients. (a) The following active ingredients may be used as the sole protectant active ingredient in a product if the ingredient as identified constitutes 50 percent or more by weight of the final product. In addition, the following active ingredients may be used in concentrations of less than 50 percent by weight only when used in combinations in accordance with § 346.22 (a), (b), or (n). (1) Aluminum hydroxide gel. (2) Cocoa butter. (3) Glycerin in a 20- to 45-percent (weight/weight) aqueous solution so that the final product contains not less than 10 and not more than 45 percent glycerin (weight/weight). Any. combination product containing glycerin must contain at least this minimum amount of glycerin. (4) Hard fat. (5) Kaolin. (6) Lanolin, (7) Mineral oil. (8) Petrolatum. (9) Topical starch. (10) White petrolatum. (b) The following active ingredients may not be used as a sole protectant ingredient but may be used in combination with one, two, or three other protectant active ingredients in accordance with § 346.22 (a), (b), (n), and (o) and with the following limitations: (1) Calamine not to exceed 25 percent by weight per dosage unit (based on the zinc oxide content of calamine). (2) Cod liver oil, provided that the product is labeled .so that the amount of the product that is used in a 24-hour period represents a quantity that provides 10,000 U.S.P. units of vitamin A and 400 U.S.P. units of cholecalciferol. (3) Shark liver oil, provided that the product is labeled so that the amount of the product that is used in a 24-hour period represents a quantity that provides 10,000 U.S.P. units of vitamin A and 400 U.S.P. units of cholecalciferol. (4) Zinc oxide not to exceed 25 percent by weight per dosage unit. § 346.16 Analgesic, anesthetic, and antipruritic active Ingredients. The active ingredient of the product consists of any of the following when used within the concentration range established for each ingredient: (a) Camphor 0.1 to 3 percent. (b) Juniper tar I to 5 percent. (c) Menthol 0.1 to 1 percent. § 346.18 Astringent active Ingredients. The active ingredient of the product consists of any of the following when used within the concentration range established for each ingredient: (a) Calamine, within a concentration range of 5 to 25 percent by weight per dosage unit (based on the zinc oxide content of calamine). (b) Hamamelis water, “The National Formulary XI,” 10 to 50 percent. (c) Zinc oxide, within a concentration range of 5 to 25 percent by weight per dosage unit. * 346.20 Keratolytic active Ingredients. The active ingredient of the product consists of any of the following when used within the concentration range established for each ingredient: (a) Alcloxa 0.2 to 2 percent. (b) Resorcinol 1 to 3 percent.
- § 346.22 Permitted combinations of anorectal active Ingredients. (a) Any two, three, or four protectants identified in (a) § 346.14 may be combined, except aluminum hydroxide gel in § 346.14(a)(1) and kaolin in § 340.14(a)(5) may not be combined with any ingredient in § 346.14(a) (2), (4), (6), (7), (8) and (10), and (b) (2) and (3), provided that the combined percentage by weight of all protectants in the combination is at least 50 percent of the Federal Register/Vol. 55, No. 150/Friday, Aug. 3, 1990/Rules and Regulations final product (e.g., I gram of a 2-gram dosage unit). Any protectant ingredient included in the combination must be present at a level that contributes at least 12.5 percent by weight (e.g., 0.25 gram of a 2-gram dosage unit), except cod liver oil and shark liver oil. If an ingredient in I 346.14(b) is included in the combination, it must not exceed the concentration limit specified in § 346.14(b). (b) Any single anorectal ingredient identified in § 348.10, 346.12. 346.16, 346.18, or 346.20 may be combined with up to four protectants in accordance with paragraph (a) of this section. (c) Any single local anesthetic identified in § 346.10 may be combined with any single vasoconstrictor identified in § 346.12. (d) Any single local anesthetic identified in 5 346.10 may be combined with any single astringent identified in § 346.18. (e) Any single local anesthetic identified in § 346.10 may be combined with any single keratolytic identified in 1 346.20. (f) Any single vasoconstrictor identified in § 346.12 may be combined with any single astringent identified in § 346.1. (g) Any single analgesic, anesthetic, and antipruritic Identified in § 346.16 may be combined with any single astringent identified in § 346.18. (h) Any single analgesic, anesthetic, and antipruritic identified in 1 346.16 may be combined with any single keratolytic identified in § 348.20. (i) Any single astringent identified in § 346.18 may be combined with any single keratolytic identified in § 346.20. 0) Any single local anesthetic identified in 1 346.10 may be combined with any single vasoconstrictor identified in § 346.12 and with any single astringent Identified in § 346.18. (k) Any single local anesthetic identified in § 346.10 may be combined with any single astringent Identified in § 346.18 and with any single keratolytic identified in § 346.20. (1) Any single vasoconstrictor identified in 1 346.12 may be combined with any single analgesic, anesthetic. and antipruritic identified in § 346.18 and with any single astringent identified in § 346.18. (in) Any single analgesic, anesthetic, and antipruritic identified in § 348.16 may be combined with any single astringent identified in 1 346.18 and with any single keratolytic identified in 9 346.20. (n) Any combination of ingredients listed in paragraphs (c) through (in) of this section may be combined with up to four protectants in accordance with paragraph (a) of this section. (o) Any product containing calamine for use as a protectant and/or as an astringent and/or containing zinc oxide for use as a protectant and/or as an astringent may not have a total weight of zinc oxide exceeding 25 percent by weight per dosage unit.
- In one aspect of the present invention, a composition including: at least one U.S. Food & Drug Administration (FDA) approved anorectal active ingredient; and at least one supplement which exhibits an activity as defined under the following categories: exhibit activity against inflammation; exhibit activity against irritation contributing to discomfort and bleeding; exhibit a calming or soothing effect; designed to reduce muscle spasm; antimicrobials that are either a direct cause of inflammation or part of the inflammatory process; dispersion agents; wound healing supplements; pain relieving supplements; and supplements which provide vascular support.
- In another aspect of the present invention, a cushioned seat for relieving tailbone and hemorrhoid pain including the following: a seat cushion dimensioned to accommodate a human sitter centered over a central section; an operative contoured surface provided along an upward-facing portion of the seat cushion, the operative contoured surface providing: a rear contour having a first elevation at both longitudinal edges and a rear edge; the first elevation being greater than other elevations of the rear contour; the rear contour slopes downward longitudinally until a transition area; both longitudinal edges sloping downward laterally toward each other and until a medial contour; the transition area sloping upwardly as it extends away from the rear contour to a lateral contour; the thing contour cresting at a second elevation and sloping downwardly to a forward contour; and the second elevation being greater than the first elevation, whereby the lateral contour raises a posterior thigh of the human sitter allowing associated buttocks and external hemorrhoids vessels to be in direct contact with the central section. In certain embodiments including a pocket disposed along the central section; and a temperature adapted element retained in the pocket, or wherein the temperature adapted element integrated to the central section.
- These and other features, aspects and advantages of the present invention will become better understood with reference to the following drawings, description and claims.
-
FIG. 1 is a perspective view of an exemplary embodiment of the present invention; -
FIG. 2 is a top view of an exemplary embodiment of the present invention, demonstrating use of a cooling pack; -
FIG. 3 is a perspective view of an exemplary embodiment of the present invention; and -
FIG. 4 is a side perspective view of an exemplary embodiment of the present invention, shown positioned on a seat. - The following detailed description is of the best currently contemplated modes of carrying out exemplary embodiments of the invention. The description is not to be taken in a limiting sense but is made merely for the purpose of illustrating the general principles of the invention, since the scope of the invention is best defined by the appended claims.
- The present invention uses “supplements” to create “enhanced” effectiveness by treating pathophysiology from a multidisciplined approach. There are many causes of anorectal symptoms therefore our invention will specify at least one supplement from the various types of supplements that may be specified depending on the formulation. These may include supplements from one or in combination with any or all the following:
-
- 1. exhibit activity against inflammation
- 2. exhibit activity against irritation contributing to discomfort and bleeding
- 3. exhibit a calming or soothing effect
- 4. designed to reduce muscle spasm (which may be associated with pain or cause other types of disfunction or symptoms)
- 5. antimicrobials (which can be either a direct cause of inflammation or part of the inflammatory process)
- 6. dispersion agents (to help the treatment spread out over a greater surface area thereby increasing the dose dependent effectiveness and onset of action)
- 7. wound healing supplements
- 8. pain relieving supplements
- 9. supplements which provide vascular support (to aid in healing and reduction of swelling)
- The present invention is described in the general context of compositions for treating hemorrhoids and conditions related to hemorrhoids as well. This includes but is not limited to anal fissures, piles, proctitis, proctospasm, abscesses, fistulas and related conditions. Additionally, such embodiments can be used to relieve or reduce pre- and post-surgical anorectal symptoms and potentially aid in healing (per scientific references on wound healing supplements if contained in one of the embodiments of the present invention).
- As used herein, the term “treatment” refers to the medical management of a patient with the intent to cure, ameliorate, stabilize, or prevent a hemorrhoids and related conditions or disorders. This term includes active treatment, that is, treatment directed specifically toward the improvement of hemorrhoids and related conditions and includes palliative treatment, that is, treatment designed for the relief of symptoms rather than the curing of hemorrhoids and related conditions.
- As used herein, the term “alleviate” or “alleviating” refers to lightening or lessening the severity of a symptom, condition, or outbreak of hemorrhoids and related conditions. For example, a treatment that reduces the severity of pain in a subject can be said to alleviate pain.
- As used herein, the term “effective amount” refers to an amount that is sufficient to achieve the desired result or to have an effect on an undesired condition. For example, a “therapeutically effective amount” refers to an amount that is sufficient to achieve the desired therapeutic result or to have an effect on undesired symptoms associated with hemorrhoids and related conditions but is generally insufficient to cause adverse side-affects. The specific therapeutically effective dose level for any particular patient will depend upon a variety of factors including the severity of the hemorrhoids and related conditions; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed and like factors well known in the medical arts.
- For example, it is well within the skill of the art to start doses of a composition at levels lower than those required to achieve the desired therapeutic effect and to gradually increase the dosage or the amount of applications of the cream until the desired effect is achieved.
- As used herein, the term “pharmaceutically acceptable carrier” refers to sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, for reconstitution into steriletopical ointments and/or creams. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, methanol, isopropanol, polyols (such as glycerol, propylene glycol, polyethylene glycol and the like), carboxymethylcellulose and suitable mixtures thereof, vegetable oils (such as olive oil, light mineral oil, cottonseed oil, castor oil, and the like) and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants.
- The term “pharmaceutically acceptable salt” refers to a salt prepared from a base or acid that is acceptable for administration to a patient, such as a mammal. Such salts can be derived from pharmaceutically acceptable inorganic or organic bases and from pharmaceutically acceptable inorganic or organic acids. Salts derived from pharmaceutically acceptable inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic, manganous, potassium, sodium, zinc and the like. Particularly preferred are ammonium, calcium, magnesium, potassium and sodium salts. Salts derived from pharmaceutically acceptable organic bases include salts of primary, secondary and tertiary amines, including substituted amines, cyclic amines, naturally-occurring amines and the like, such as arginine, betaine, caffeine, choline, N,N′-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperadine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine and the like. Salts derived from pharmaceutically acceptable acids include acetic, ascorbic, benzenesulfonic, benzoic, camphosulfonic, citric, ethanesulfonic, fumaric, gluconic, glucoronic, glutamic, hippuric, hydrobromic, hydrochloric, isethionic, lactic, lactobionic, maple, malic, mandelic, methanesulfonic, mucic, naphthalenesulfonic, nicotinic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric (providing a tartrate or bitartrate), p-toluenesulfonic and the like. Particularly preferred are citric, hydrobromic, hydrochloric, maple, phosphoric, sulfuric and tartaric acids.
- The terms “anorectal disease”, “painful conditions of the anal region”, “anal conditions”, “anal pain”, and the like, are used herein to describe symptoms of discomfort or pain in a person's anorectal area, or the diseases and disorders that produce them. Anorectal diseases include anal fissures, thrombosed or inflamed hemorrhoids, pain associated with the aftereffects of anal surgery and procedures (such as rubber-band ligation of internal hemorrhoids) and chronic anal pain. The anorectal area comprises the anal mucosa, the mucosa of the most distal portion of the rectum, the internal and external anal sphincters, the skin immediately surrounding the anus.
- FDA Classification “Active agent” or “Active ingredient”, as used herein, refers to any component in a composition of the present invention that has been approved for use in anorectal disorders by the FDA (and referenced in the anorectal monograph) because of their known ability to reduce the symptoms associated with anorectal disease.
- “Supplements” differ from “active agent” or “Active ingredient”, as used herein, to mean any component that can be added to a composition that has some biological effect according to a consensus of reference guides on supplements, whether the biological effect is directly related to anorectal disease or not. The biological effect is preferably curative. Such components might have analgesic or anesthetic effects, Such components might alternatively have an activity unrelated to pain reduction such as anti-inflammatory effect, muscle relaxing effects, vascular support effects, calming effects, improved dispersion, and anti-microbial effects as examples.
- There are no standard concentrations provided for supplements by the FDA so none will be specified. Additionally, while the FDA does recognize the use of supplements with certain guidelines and provisions, the marketing of such claims are limited so that the inclusion of such ingredients may be listed as “inactive ingredients”.
- Xylocaine has the generic name lidocaine and may be used as an active ingredient of the composition of the present invention (other FDA approved anesthetics may also be used and are listed in the anorectal monograph). Lidocaine is an intermediate-duration anesthetic, that is incorporated into the gel, lotion, paste, wipe or solution of the present invention and can be safely applied within an effective dosage protocol topically usually every 3-4 hours to obtain relief of pain. If used, the FDA specified concentration ranges from as low as 2% to as high as 5%. Lidocaine is a local anesthetic and antiarrhythmic drug. Lidocaine is used topically to relieve itching, burning and pain from skin inflammations that is often associated with hemorrhoids and related conditions. Together with phenylephrine HCl (which is one example of an FDA approved vasoconstrictor), these two ingredients work to shrink and relieve pain and itching associated with hemorrhoids and related conditions almost immediately. The topical treatment of the present invention may consist of a single application of a treatment containing concentrations of phenylephrine HCl and lidocaine permitted by the Food and Drug Administration (FDA) in combination with a supplement which is sufficient for some outbreaks of an anorectal condition but most cases require multiple applications.
- The compositions of the present invention can also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganism contamination can be ensured by the inclusion of various antibacterial and antifungal agents such as glycerin, capryl hydroxamic acid, paraben, chlorobutanol, phenol, sorbic acid, chlorohexidine digluconate, and the like. Antioxidants, such as BHT, can be included. It can also be desirable to include isotonic agents such as sugars, sodium chloride and the like.
- The inventor contemplates that any conventional adjuvants can be used in the present composition. These may include antioxidants, for example sodium or potassium metabisulfite; isotonic agents such as sodium chloride; chelating agents such as EDTA or citric acid; pH adjustment agents such HCl or NaOH, present in an amount desirable to achieve a pH of, for example, from 3.3-5.5; minor impurities such as aluminum salts; and other ingredients. Other adjuvants that may find use herein include opiates, such as morphine and fentanyl (used to provide epidural/spinal anesthesia); NMDA antagonists, such as dextromethorphan; clonidine; antiinflammatory agents; antibiotics; and the like. When preparing the pharmaceutical compositions of this invention, the active ingredient is customarily diluted by an excipient. Representative examples of suitable excipients include water, sterile saline, syrup, and methylcellulose. The formulations can additionally include emulsifying and suspending agents; preserving agents, such as methyl- and propylhydroxy-benzoates; and flavoring and coloring agents.
- The compounds of this invention may be formulated using conventional techniques such as those described in Remington's Pharmaceutical Sciences, Mace Publishing Co., Philadelphia, Pa. 17th Ed. (1985) and “Modern Pharmaceutics,” Marcel Dekker, Inc. 3.sup.rd Ed. (G. S. Banker & C. T. Rhodes, Eds.). Pharmaceutically acceptable salts of the active agents (e.g., acid addition salts) may be prepared using standard procedures known to those skilled in the art of synthetic organic chemistry and described, e.g., by J. March, Advanced Organic Chemistry: Reactions, Mechanisms and Structure, 4th Ed. (New York: Wiley-Interscience, 1992).
- In one embodiment of the present invention, the composition designed to treat hemorrhoids and related conditions comprises what the FDA recognizes as a therapeutic effective amount of phenylephrine HCl (or other FDA approved vasoconstrictor) for relieving swelling caused by hemorrhoids and related conditions. Phenylephrine HCl is an active ingredient of the ointment that acts to shrink the swollen tissues associated with hemorrhoids by constricting blood vessels that feed blood and fluid to the area around the hemorrhoid. Phenylephrine HCl is a α-adrenergic receptor agonist that binds to α-adrenergic receptors that once activated set off a physiological process in the body that restricts blood supply to the area of the hemorrhoids and thereby reduces swelling in this area. Although very effective, the favorable effects of phenylephrine HCl on hemorrhoids are often masked by the itching and pain in the area around the hemorrhoid(s). To relieve this pain the present invention may also include lidocaine, or any other FDA monograph approved analgesic, anesthetic, antipruritic or astringent ingredient.
- To enhance the effects of the topical treatment of the present invention, without adding more than the FDA approved amounts of the active ingredients discussed above, supplements are added to the topical treatment. These supplements can be used alone, in combination with other supplements which exhibit similar characteristics, or with supplements which exhibit different characteristics many of which can be described below. Examples of references supporting the use of supplements for these indications include:
-
- 1. Culpeper's Complete Herbal: Over 400 Herbs and Their Uses
- Arcturus Publishing Limited Jan. 30, 2012
- 2. The Herb Society of America
- Encyclopedia of Herbs & Their Uses
- By Deni Bown
- Dorling Kindersley Publishing Inc. 1995
- 3. https://examine.com/4.
- 4. Encyclopedia of Dietary Supplements Second Edition
- Informa Healthcare, 52 Vanderbilt Avenue, 7th floor, New York, N.Y. 10017, USA 2010
Examples of the most desirable characteristics of the supplements being used consist of the following list which is not all-inclusive:
- Informa Healthcare, 52 Vanderbilt Avenue, 7th floor, New York, N.Y. 10017, USA 2010
- 1. exhibit activity against inflammation
- 2. exhibit activity against irritation contributing to discomfort and bleeding
- 3. exhibit a calming or soothing effect.
- 4. designed to reduce muscle spasm (which can be associated with pain)
- 5. antimicrobials (which can be either a direct cause of inflammation or part of the inflammatory process)
- 6. dispersion agents (to help the treatment spread out over a greater surface area thereby increasing the dose dependent effectiveness and onset of action)
- 7. wound healing supplements
- 8. pain relieving supplements
- 9. supplements which provide vascular support.
- 1. Culpeper's Complete Herbal: Over 400 Herbs and Their Uses
- These supplements can be safely used in combination with phenylephrine HCl and lidocaine or any other FDA approved anorectal active ingredient to enhance the potency and extend the period of effectiveness of the topical treatment of the present invention. Examples of the effects these supplements can exhibit is further described below.
- Camellia sinensis [also known as tea tree] as an example is—rich in flavonoids including anthocyanins, oligomeric proanthocyanidins (OPCs), quercetin and isoquercitrin and have astringent and other properties. Clinical trials have proven the efficacy of preparations made from many supplements such as horse chestnut and Gotu Cola as examples in the treatment of venous insufficiency. These effects have been in reducing significantly lower leg edema and circumference whilst improving other chronic symptoms to a clinically relevant extent. This relates to increased pressure typically found in hemorrhoid disease in which such reduction of pressure can effectively reduce or resolve prolapsing or protruding hemorrhoids.
- As stated above, Camellia sinensis contain a wide range of polyphenol flavonoids including flavon (op-glycosides and glucuronides, quercetin-3-O-beta-D-glucuronide (main flavonoid), isoquercitrin, anthocyanins, oligomeric proanthocyanidins, catechin, epicatechin monomers and dimers; gallic acid and astilbine. Turmeric as another example reduces swelling and compliments the active ingredient phenylephrine HCl. The proposed mechanism of action by which Turmeric (curcumin) induces its anti-inflammatory effects is yet to be fully elucidated. Studies have shown that peroxisome proliferator-activated receptor gamma (PPAR-γ) has been associated with anti-inflammatory effects. PPARs belong to the superfamily of nuclear receptors consisting of three genes that give rise to three different subtypes, PPAR-α, PPAR-δ, and PPAR-γ. Among them, PPAR-γ is the most widely studied form. Upon ligand binding, PPAR-γ forms heterodimers with the retinoid X receptor and binds to a peroxisome proliferation response element (PPRE) in a gene promoter leading to regulation of gene transcription. In that regard, we have recently shown that gene and protein levels of PPAR-γ in the liver decreased by approximately 50% at 20 hours after the onset of sepsis. Pretreatment with curcumin for 3 days at 0.24 μmol/kg body weight in these septic rats produced 45% and 65% increase in PPAR-γ mRNA and protein levels, respectively.
- Since they have a different mode of physiological operation than phenylephrine HCl they last for a longer period of time than phenylephrine HCl thereby extending the effectiveness of the topical treatment of the present invention.
- In addition to these ingredients, the topical treatment of the present invention may also include Lavender Oil. which is another example of a supplemental ingredient that complements the active ingredients of the present invention. This is effective in further reducing inching and soothing the area around the hemorrhoid(s). Punica granatum is an astringent that helps to heal open wounds and therefore aids in reducing bleeding and itching often associated with hemorrhoids and related conditions.
- The topical treatment of the present invention combines both conventional medical compositions such as phenylephrine HCl and lidocaine with supplemental compositions such as horse chestnut, chamomile, etc. to produce a topical treatment that is more potent for treating hemorrhoids and related conditions than other topical treatments that use conventional ingredient or supplemental ingredients alone. In certain embodiments, such treatments may provide effects which are not able to be achieved using traditional FDA approved active ingredients. In addition, the overlapping of ingredients that has cumulative and complementary affects aids in prolonging the therapeutic effects of the claimed topical treatment as compared to other topical treatments for treating anorectal disorders available on the market today. That is, the claimed topical treatment enhances this by adding additional ingredients beyond what the FDA provides for and considers “active” in the anorectal monograph. These supplemental ingredients enhance the potency of the claimed topical treatment as well as extend the duration of effectiveness.
- The compositions of the present invention are typically administered in a therapeutically effective amount. It will be understood, however, that the amount of the compound administered will be determined by the FDA dosing recommendations governing the active drug ingredients.
- In one preferred embodiment, the treatment comprises 4% to 5% by weight of lidocaine and 0.25% by weight of phenylephrine HCl as active ingredients and algae extract, chamomile, Ginseng, and Sodium Hyaluronate as supplemental ingredients. The topical treatment may also be comprised of additional or different active ingredients as well as different supplemental ingredients and combined with non-active components including benzyl alcohol, carbomer, cholesterol, hydrogenated lecithin, isopropyl myristate glycol, triethanolamine, Vitamin E Acetate, and purified water, fragrances, coloring agents, vitamins, oils, stability agents and/or other ingredients necessary to maintain the effectiveness of the topical treatment.
- The carbomer polymers of the ointment are used as thickening, dispersing, and emulsifying agents. They are also used to control the release of medicaments from time-release tablets or from entrapped systems. Carbomers are largely insoluble in water and in the majority of common solvents. When neutralized (with bases, e.g., hydroxides or amines), Carbomers can be soluble in water, alcohol and glycerin. Carbomers are hygroscopic in nature, swelling to many times their original volume when in contact with a solvent. Such swollen particles remain discrete in various mucilaginous or colloidal dispersions. Although swelling is inherently caused by their hydrophilic nature, “maximum volume swell” does not typically occur in water until the polymers are converted to partial organic or inorganic salts. The increased volume is generally stable at all pH levels but increases as neutralization increases. Maximum volume occurs at 50-90% neutralization, with a neutralization of 75% normally occurring at pH 7.0.
- The topical treatment composition of the present invention is made by mixing the active ingredients and supplemental ingredients into a pharmaceutically acceptable carrier and adding the other ingredients as well as water in an order that provides a topical cream, ointment, lotion, gel, spray, suppository, wipe etc. wherein the activity of the conventional and supplemental ingredients are maintained. Conventional producing procedures used in the art can also be used to make the desired composition of the present invention.
- For example one method that can be used to produce the water-based topical ointment of the present invention includes the steps of: providing a mixture of aqueous solvent, one or more penetration enhancers, and, optionally, one or more preservatives; adding to the mixture one or more thickeners; adding to the mixture one or more emulsifiers; heating the mixture to at least a temperature sufficient to solubilize or melt the one or more thickeners and/or one or more emulsifiers; adding phenylephrine HCL and lidocaine as well as the supplemental ingredients; and adjusting the pH of the mixture to from about 4 to about 6 with a pH-adjuster.
- In a further aspect, the pH is adjusted before or during one or more of the providing, adding, and heating steps. In a yet further aspect, the pH is adjusted after the providing, adding, and heating steps. In one aspect, the ointment comprises at least about 60% aqueous solvent by weight. Typically, the mixture is provided as a uniform suspension (dispersion) of ingredients. In certain aspects, the mixture can appear as an emulsion or a solution. It is understood that this method is just one method that can be used to make the ointment of the present invention but other methods available in the art can also be used.
- Once the topical treatment composition is produced it can be provided in a single dosage convenient packaging, a squeezable tube, a wide-mouth jar, saturated on a pad for application, suppository sheet, or any other suitable storage means.
- As dictated elsewhere it is understood that the compositions of the disclosed invention can be provided in a form suitable for topical use such as, for example, cream, ointment, lotion, gels and the like. Further, the compositions can be in a form suitable for use in transdermal devices as well such as wipes, clothes, applicators, pads, and other applications including specifically designed under garments that are designed to keep the ointment in place. All these formulations can be prepared via conventional processing methods as discussed above.
- In addition, although anorectal disorders are explicitly discussed throughout the application it is understood that the composition can be used with many specific anal conditions including but not limited to hemorrhoids, anal fissures, anal tears, anal scarring and the like.
- Finally, it is understood that the topical treatment of the present invention can be included as part of a kit that contains a hemorrhoid reducing/comfort seat as well as instructions for using the seat and applying the topical treatment thereafter.
- The present invention includes a specialized foam comfort cushion with a mesh pocket to hold a cold or hot gel insert or electric heating pad. This cushion can be sat on comfortably and the gel insert will provide direct cold or heat as desired to the external hemorrhoidal cushions. Cold therapy has been found to reduce inflammation, swelling and soreness. Cold is typically recommended as an anti-inflammatory during the first 24 hours of injury as an example in the case of a ruptured external hemorrhoid blood vessel causing an external thrombotic hemorrhoid. Heat therapy can help relieve discomfort by providing a warm, comforting sensation. Heat also helps increase blood flow throughout the body. Increased blood flow can heal injuries faster. In the case of a thrombosed external hemorrhoid as an example, heat is advised after 24 hours to improve vascular circulation thereby allowing improved blood flow and drainage thereby allowing reabsorption of the clot(s).
- Therefore, the present invention is also directed to the method of treating hemorrhoids and related conditions by applying the topical treatment of the present invention either alone or in combination with the use of a cushion device designed to provide comfort while applying heat or cold directly to the perianal location so as to alleviate discomfort, reduce swelling, improve healing or as an example, cause an external thrombosis to be reabsorbed by the body. This does not eliminate the itching and swelling often associated with this condition; however, the topical treatment of the present invention is designed to reduce these symptoms as discussed above.
- Referring to
FIGS. 1 through 4 , the present invention may include a sitting cushion integrating heating and cooling elements and adapted in shape to relieve tailbone and hemorrhoid pain. The uniquely adapted treatment seat integrates hot or cold pads into a sitting cushion for providing significant enhanced pain relief and comfort. Thereby, the present invention “solves the problem” of providing both a comfortable surface to sit on while applying heat or cold to relieve lower back, tailbone and hemorrhoid discomfort. - It should be understood by those skilled in the art that the use of directional terms such as upper, lower, upward, downwardly, top, left, right and the like are used in relation to the illustrative embodiments as they are depicted in the figures, the upward direction (or upper) being toward the top of the corresponding figures, downward direction being toward the bottom of the corresponding figures.
- The present invention includes a
seat portion 10 providing astorage space 12 for removably retaining heating-cooling elements 18. Theseat portion 10 may be a sitting cushion having a uniquely shaped operative contouredsurface 16. Thestorage space 12 may be a mesh pocket applied to cushion sewed or adhered using adhesive material sitting cushion. The heating-cooling elements 18 may be gel pad which can be cooled in freezer and/or heated in a microwave and slid into anopening 14 of the pocket/compartment 12. - A method of manufacturing the present invention may include, the following. A manufacturer may first cut the mesh pocket in a size and shape to assure coverage of the affected areas designed to be treated by the apparatus, mainly the tailbone, lower back and external hemorrhoid (peri-anal) regions. This area can vary in size and shape as long as it provides coverage for the affected regions. The mesh pocket may be attached to the sitting cushion by way of sewing or any chemical adhesion method. A gel pad may be used which will fit into the mesh pocket and be large enough to provide coverage for the affected area. The gel pad may be either heated or cooled and subsequently to being placed into the mesh pocket.
- The manufacturer may start from a generic sitting cushion, attach the mesh pocket to the sitting cushion and place a gel pad which has been heated in a microwave (or other generic heating apparatus) or cooled in the freezer (or other cooling apparatus).
- The pocket and pad must be measured to provide coverage to the tailbone, lower back and perianal (hemorrhoid) region. The contours the operative contoured
surface 16 are dimensioned and adapted so that when the user arrives at the appropriate size, thepocket 12 andtemperature element 18 are cut to the appropriate size and the pocket (or electrical stimulation pad) is attached to the sittingcushion 10 using adhesives or stitching. The back of the operative contouredsurface 16 may have a slight raised area to able to rest the lower back while helping to provide a guide so that the subject is correctly positioned on the operative contouredsurface 16 of thecushion 10. A lateral contour may raise posterior thigh allowing buttocks and specifically lower spine and external hemorrhoids vessels to be in direct contact with the heating-cooling element 18. The lateral contour may achieve a maximum elevation (relative to the bottom surface) approximately eight inches from the rear of theseat portion 10 and then slope continuously downward in a forward direction. As a result, theseat portion 10 may provide an elevated posterior thigh causing flexion at the hip, when the present invention is placed on a seat 20 with the operative contouredsurface 16 upward-facing. - In one embodiment, the operative contoured
surface 16 provides an angled support surface (due to the angle of inclination of the surfaces) including a pair of spaced apartthigh contours 30 defining ananorectal portion 40 dimensioned and adapted accommodate a human sitters anorectal/anus when seated on the operative contouredsurface 16.Thigh contours 30 are concave shapes configured to spread the sitter's thighs so as to evenly distribute pressure from theanorectal portion 40 onto the anorectal/anus of the sitter. Theanorectal portion 40 is where the heating-cooling element 18 is disposed so as to be urged against the ‘spread’ anus of the sitter. - The temperature adaptive element may be a “hot or cold” gel insert. Heat is better for enhanced relaxation and increased circulation related to anorectal disorders associated with muscle spasm, anal fissures as an example as well as external thrombotic hemorrhoids since the heat will help to dissolve the clots. Cold as discussed elsewhere, aids in reducing inflammation and works best to alleviate pain.
- In an
alternative embodiment 22, other elements which could be beneficial would be to attach an electrical stimulation device to the area currently designed to contain the mesh pocket and gel pad. Attaching an electrical stimulation device to a sitting cushion (in the area currently designed to contain the mesh pocket and gel pad) would also allow relief of low back, tailbone and hemorrhoid pain and discomfort. The apparatus would differ by applying an electrical stimulation pad instead of a pocketed gel pad—i.e., relief would be accomplished by using muscle stimulation verses temperature-initiated relief based on cold (anesthesia and anti-inflammatory) or heat (soothing and improved circulatory response). Additionally, theintegrated element 24 of thealternative embodiment 22 could be integrated along the operative contouredsurface 16 of thetherapeutic cushion 10. - While the invention has been illustrated and described with respect to specific illustrative embodiments and modes of practice, it will be apparent to those skilled in the art that various modifications and improvements may be made without departing from the scope and spirit of the invention. Accordingly, the invention is not to be limited by the illustrative embodiments and modes of practice.
- Said mixtures and combinations thereof, most likely will require at least one topical carrier selected from the group consisting of creams, ointments, gel, lotions, foam and mixtures and combinations thereof, wherein said composition is designed for internal and or external topical use and application, and said composition is designed to relieve one or all of the following: swelling, burning, pain and itching, irritation, inflammation, protrusion as well as protect inflamed and or irritated tissues, or provide a cooling sensation to the various signs and symptoms caused by various disorders afflicting the anus and rectum.
- It should be understood, of course, that the foregoing relates to exemplary embodiments of the invention and that modifications may be made without departing from the spirit and scope of the invention as set forth in the following claims.
Claims (1)
1. A composition comprising:
at least one U.S. Food & Drug Administration (FDA) approved anorectal active ingredient; and
at least one supplement exhibiting at least one characteristic selected from the group consisting of:
i. exhibit activity against inflammation;
ii. exhibit activity against irritation contributing to discomfort and bleeding;
iii. exhibit a calming or soothing effect;
iv. designed to reduce muscle spasm;
v. antimicrobials that are either a direct cause of inflammation or part of the inflammatory process;
vi. dispersion agents;
vii. wound healing supplements;
viii. pain relieving supplements; and
ix. supplements which provide vascular support.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/804,342 US20220287862A1 (en) | 2019-01-24 | 2022-05-27 | Topical treatment for anorectal disorders with and without seat cushion |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962796194P | 2019-01-24 | 2019-01-24 | |
US16/750,372 US11576801B2 (en) | 2019-01-24 | 2020-01-23 | Topical treatment for anorectal disorders with and without seat cushion |
US17/804,342 US20220287862A1 (en) | 2019-01-24 | 2022-05-27 | Topical treatment for anorectal disorders with and without seat cushion |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/750,372 Division US11576801B2 (en) | 2019-01-24 | 2020-01-23 | Topical treatment for anorectal disorders with and without seat cushion |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220287862A1 true US20220287862A1 (en) | 2022-09-15 |
Family
ID=71733150
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/750,372 Active 2040-11-02 US11576801B2 (en) | 2019-01-24 | 2020-01-23 | Topical treatment for anorectal disorders with and without seat cushion |
US17/804,342 Pending US20220287862A1 (en) | 2019-01-24 | 2022-05-27 | Topical treatment for anorectal disorders with and without seat cushion |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/750,372 Active 2040-11-02 US11576801B2 (en) | 2019-01-24 | 2020-01-23 | Topical treatment for anorectal disorders with and without seat cushion |
Country Status (1)
Country | Link |
---|---|
US (2) | US11576801B2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11641960B2 (en) * | 2020-05-05 | 2023-05-09 | Mlilyusa, Inc | Cooling bedding product |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU3850395A (en) * | 1994-11-09 | 1996-06-06 | Wyeth | Hemorrhoidal compositions and method of use |
US5932230A (en) * | 1997-05-20 | 1999-08-03 | Degrate; Frenchell | Topical analgesic formulation containing fruits, oils and aspirin |
US6228387B1 (en) * | 2000-01-27 | 2001-05-08 | Murray Borod | Integrated comprehensive hemorrhoid treatment compositions and regimen |
JP2004131472A (en) * | 2002-08-09 | 2004-04-30 | Taisho Pharmaceut Co Ltd | Ointment for treatment of hemorrhoid |
US20040122105A1 (en) * | 2002-09-20 | 2004-06-24 | Griscom Bettle | Transdermal compositions |
JP2005029529A (en) * | 2003-07-09 | 2005-02-03 | Tendou Seiyaku Kk | Therapeutic agent for hemorrhoid |
US20050186171A1 (en) * | 2004-02-23 | 2005-08-25 | Winick Bernyce A. | Skin cream |
US20100247563A1 (en) * | 2009-03-30 | 2010-09-30 | Mary Kay Inc. | Topical skin care formulations |
WO2015185979A1 (en) * | 2014-06-04 | 2015-12-10 | Peritech Pharma Ltd. | Anorectal compositions comprising an anesthetic as free base and a vasoconstrictor as salt |
US10238704B2 (en) * | 2013-12-20 | 2019-03-26 | Pfizer Inc. | Pre moistened wipes for use in treating anal rectal irritations and disorders |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3359577A (en) * | 1966-05-19 | 1967-12-26 | Lee C Rogers | Back support |
USD276938S (en) * | 1980-05-01 | 1984-12-25 | Erling Pedersen | Surgical pillow |
USD279642S (en) * | 1982-08-25 | 1985-07-16 | Ross Robert M | Portable orthopedic back rest |
USD289481S (en) * | 1984-12-19 | 1987-04-28 | Kenneth T. Reddick | Sacrum cushion |
US4761843A (en) * | 1985-05-20 | 1988-08-09 | Jay Medical, Ltd. | Hemorrhoid seat cushion |
US4858259A (en) | 1987-01-12 | 1989-08-22 | Simmons Ethel D | Therapy pillow with removable therapeutic gel pack |
US4805603A (en) * | 1988-07-13 | 1989-02-21 | Keith Cumberland | Inflatable cervical traction pillow |
WO1994000087A1 (en) | 1992-06-22 | 1994-01-06 | Ergomed, Inc. | Versatile therapeutic cold pack |
US5626387A (en) * | 1995-02-27 | 1997-05-06 | Yeh; Ching-Hsiu | Cushion with cooling stubs |
US5545199A (en) | 1995-07-03 | 1996-08-13 | Hudson; Gary C. | Hot and cold therapeutic pillow |
US5948013A (en) | 1996-07-16 | 1999-09-07 | Swezey; Robert L. | Self-inflating back pillow and cold therapy device |
US5895656A (en) | 1996-10-18 | 1999-04-20 | Life Medical Sciences, Inc. | Gas or gel-filled silicone cushion for treatment of keloid and hypertrophic scars |
US5800491A (en) | 1997-02-03 | 1998-09-01 | Kolen; Paul T. | Thermal therapy devices and methods of making the same |
DE29805926U1 (en) * | 1998-04-01 | 1999-07-29 | Johnson Controls Gmbh | Seat pads for vehicle seats |
US6009578A (en) | 1998-10-08 | 2000-01-04 | Davis; Steve | Seat cushion |
US5916088A (en) | 1998-10-26 | 1999-06-29 | Gueli; Martin | Cooling beach pillow |
US6132455A (en) | 1999-02-05 | 2000-10-17 | Shang; Li-Jun | Cooling comfort seat cushion |
USD444980S1 (en) * | 1999-07-20 | 2001-07-17 | Bruce Mowat | Ergonomic pillow |
CA2388828A1 (en) | 1999-10-22 | 2001-06-14 | Transdermatech, Inc. | Topical anesthetic formulation |
US6409748B1 (en) | 1999-11-16 | 2002-06-25 | Sunbeam Products, Inc. | Heating pad with removable gel pack |
EP1319397B1 (en) | 2000-09-21 | 2005-08-17 | Taisho Pharmaceutical Co., Ltd | Suppositories sustained in the lower rectum |
US6645235B1 (en) | 2000-10-06 | 2003-11-11 | Linda R. Blackwell | Hot/cold pack device |
US20030032996A1 (en) | 2001-08-08 | 2003-02-13 | Hallman Arlan Jay | Cryogenic massage tube and compress |
US6704957B2 (en) * | 2002-07-31 | 2004-03-16 | Steven L. Rhodes | Patient support pad for medical imaging equipment |
US7704518B2 (en) | 2003-08-04 | 2010-04-27 | Foamix, Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
US20060004094A1 (en) | 2004-07-02 | 2006-01-05 | Agisim Gary R | Composition and method for treating hemorrhoids and/or anorectal disorders |
US7272936B2 (en) | 2004-12-28 | 2007-09-25 | Steve Feher | Variable temperature cushion and heat pump |
DE102005026107A1 (en) * | 2005-06-07 | 2006-12-14 | Uwe Schramm | Therapeutic underlay, for physiotherapy to mobilize separate spine segments, is of a material with shape stability with a main raised section and a lower raised section at the end |
US7331184B2 (en) | 2005-09-14 | 2008-02-19 | Ching-Yang Lee | Hot-cold cushion |
US20070148105A1 (en) | 2005-12-22 | 2007-06-28 | Donald Spector | Compositions and methods comprising magnetic particles for health use |
US7879344B2 (en) | 2006-06-29 | 2011-02-01 | Kimberly-Clark Worldwide, Inc. | Transdermal delivery of oleocanthal for relief of inflammation |
US20080136231A1 (en) | 2006-09-01 | 2008-06-12 | Brian Doherty | Infant and child car seat for thermally conditioning a body |
US20090169652A1 (en) | 2007-11-29 | 2009-07-02 | Rosemarie Osborne | Personal Care Compositions |
US8636988B2 (en) | 2008-01-31 | 2014-01-28 | Doctor Essentials | Composition for treatment of sunburned skin |
US20100237082A1 (en) | 2009-03-20 | 2010-09-23 | Products Of Tomorrow, Inc. | Gel cushion mat |
US8556337B1 (en) | 2009-07-02 | 2013-10-15 | Tammy L. Cornitius-Cary | Thermal cooling/heating seat/backrest cover |
USD634961S1 (en) * | 2010-05-31 | 2011-03-29 | Lowery William T | Pillow |
WO2011160095A2 (en) | 2010-06-18 | 2011-12-22 | Claudia Rimoli | Multifunctional lumbar support pillow |
US20170128392A1 (en) * | 2010-08-11 | 2017-05-11 | John Maurello | System for treatment of hemorrhoids |
US9545391B2 (en) | 2010-08-11 | 2017-01-17 | Hemaway Llc | Medicated ointment for treating hemorrhoid and method of using the same |
US8937212B2 (en) | 2010-08-24 | 2015-01-20 | Michelle Fogg | Feminine cooling pad |
USD716072S1 (en) * | 2011-02-21 | 2014-10-28 | Christina Rose | Ergonomic pillow |
US9358151B2 (en) | 2011-09-08 | 2016-06-07 | Nancy Kathleen Peardon | Therapeutic cooling pillow |
US20140008945A1 (en) | 2012-06-26 | 2014-01-09 | Donald G. Widmann | Cool Seat |
USD695365S1 (en) * | 2012-12-06 | 2013-12-10 | Ncc Co., Ltd. | Stretching device |
US20150040324A1 (en) | 2013-08-07 | 2015-02-12 | Skytex, Inc. | Seasonal Memory Pillow |
US20150257554A1 (en) | 2014-03-11 | 2015-09-17 | E & B Giftware Llc | Air-activated heated travel pillows and travel blankets |
US10238222B2 (en) | 2014-09-05 | 2019-03-26 | Raj Rao | Electronically controllable pillow |
US9549617B1 (en) | 2015-04-20 | 2017-01-24 | Axis Sourcing Group, Inc. | Chair back cooler |
USD808194S1 (en) * | 2015-09-04 | 2018-01-23 | Hyoumankind Limited | Pillow |
US10791845B2 (en) * | 2018-01-02 | 2020-10-06 | Gary TACON | Therapeutic cushion |
US10913535B2 (en) * | 2019-01-21 | 2021-02-09 | B/E Aerospace, Inc. | Cushion assembly with elastomeric lattice insert |
-
2020
- 2020-01-23 US US16/750,372 patent/US11576801B2/en active Active
-
2022
- 2022-05-27 US US17/804,342 patent/US20220287862A1/en active Pending
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU3850395A (en) * | 1994-11-09 | 1996-06-06 | Wyeth | Hemorrhoidal compositions and method of use |
US5932230A (en) * | 1997-05-20 | 1999-08-03 | Degrate; Frenchell | Topical analgesic formulation containing fruits, oils and aspirin |
US6228387B1 (en) * | 2000-01-27 | 2001-05-08 | Murray Borod | Integrated comprehensive hemorrhoid treatment compositions and regimen |
JP2004131472A (en) * | 2002-08-09 | 2004-04-30 | Taisho Pharmaceut Co Ltd | Ointment for treatment of hemorrhoid |
US20040122105A1 (en) * | 2002-09-20 | 2004-06-24 | Griscom Bettle | Transdermal compositions |
JP2005029529A (en) * | 2003-07-09 | 2005-02-03 | Tendou Seiyaku Kk | Therapeutic agent for hemorrhoid |
US20050186171A1 (en) * | 2004-02-23 | 2005-08-25 | Winick Bernyce A. | Skin cream |
US20100247563A1 (en) * | 2009-03-30 | 2010-09-30 | Mary Kay Inc. | Topical skin care formulations |
US10238704B2 (en) * | 2013-12-20 | 2019-03-26 | Pfizer Inc. | Pre moistened wipes for use in treating anal rectal irritations and disorders |
WO2015185979A1 (en) * | 2014-06-04 | 2015-12-10 | Peritech Pharma Ltd. | Anorectal compositions comprising an anesthetic as free base and a vasoconstrictor as salt |
Also Published As
Publication number | Publication date |
---|---|
US11576801B2 (en) | 2023-02-14 |
US20200237544A1 (en) | 2020-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100950524B1 (en) | Topical glycopyrrolate product | |
US8137711B2 (en) | Methods of treating neuropathy | |
Stolman | Treatment of hyperhidrosis | |
JP4352114B2 (en) | Arginine medication with beneficial effects | |
US5504117A (en) | Pharmacologic preparation for the treatment of anal disorders | |
CN112165960A (en) | Composition for treating chronic wounds | |
JP2001504463A (en) | Pharmaceutical composition containing Kukunoki nut oil | |
JP2002515401A5 (en) | ||
EP1789433A2 (en) | Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists | |
WO2008031322A1 (en) | Application of acetylcholine esterase inhibitor medication of leonurus extractive as cholinomimetic | |
US20170128392A1 (en) | System for treatment of hemorrhoids | |
EP0506658B1 (en) | Compositions and method for treating painful, inflammatory or allergic disorders | |
US11007241B2 (en) | Compositions for relieving pain with malkangni oil and cypriol oil as active ingredients and method of topical administration of the same | |
US9545391B2 (en) | Medicated ointment for treating hemorrhoid and method of using the same | |
JP2022512584A (en) | EGFR inhibitor for treating keratoderma | |
US20220287862A1 (en) | Topical treatment for anorectal disorders with and without seat cushion | |
US8053004B2 (en) | Ointment for topical treatment of hot flashes and method of use | |
US10960011B2 (en) | Compositions for the treatment of ischemic ulcers and stretch marks | |
WO2001064229A1 (en) | A medicine for treating obesity and the method of producing thereof | |
WO2017043350A1 (en) | Anti-itching agent | |
CN110269926A (en) | Middle benefit gas, which is relaxed, warms up composition and its preparation method and application | |
CN116570700B (en) | Traditional Chinese medicine preparation with antibacterial, anti-inflammatory and acne removing effects and application thereof | |
KR20120102214A (en) | A medicine for external application of natural and oriental herb complex | |
JP2007308403A (en) | Skin care preparation | |
ITMI20120462A1 (en) | EXTRACT OF RHUS CORIARIA L. FOR USE IN THE TREATMENT OF HYPERHIDROSIS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |